Galvus Met > He hoʻomaʻemaʻe a me ke pale aku

ʻO ka wehewehe e pili ana i 23.11.2014

Palapala Latin: Ua hālāwai ʻo Galvus
Manaʻo SAX: A10BD08
Mea waiwai: Vildagliptin + Metformin (Vildagliptin + Metformin)
Mea Hana: Novartis Pharma Production GmbH., Kelemānia, Novartis Pharma Stein AG, Switzerland

Aia i nā papa nā papa kaiola: vildagliptin a metformin hydrochloride.

Nā kumuwaiwai hou: hyprolose, hypromellose, magnesium stearate, titanium dioxide, talc, macrogol 4000, hao oxide melemele a ʻulaʻula.

Nā hōʻailona no ka hoʻohana ʻana

Hoʻohana ʻia ka lāʻau lapaʻau i ka mālama ʻana i ka maʻi type 2.

ʻo ka mea wale nō i ke ʻano me ka meaʻai a me ka hana kino kino Hōʻike i hōʻike mai ka mālama ʻana i ka hopena mau loa,
i ka hui ʻana me metformin i ka hoʻomaka ʻana o ka lāʻau lapaʻau, me ka hopena ʻole o kaʻai ʻana a me ka hoʻonui ʻana i ke ʻano kino,
no nā poʻe e hoʻohana i nā analogues e pili ana i ka vildagliptin a me ka metformin, no ka laʻana o Galvus Met.
no ka paʻakikī o nā lāʻau lapaʻau e pili ana i ka vildagliptin a me ka metformin, a me ka hoʻohui ʻana i nā lāʻau me ka sulfonylureas, thiazolidinedione, a i ʻole insulin. Hoʻohana ʻia ia i nā hihia o ka mālama ʻana me ka monotherapy, a me ka ʻaina a me ka hana kino kino,
ma ke ʻano he triple therapy i ka waiho ʻole ʻana o ka hopena o ka hoʻohana ʻana i nā lāʻau lapaʻau e pili ana i ka sulfonylurea a me nā derivatives metformin, i hoʻohana mua ʻia ma ka ʻano o ka ʻaina a me ka hoʻoikaika kino kūlohelohe,
ma ke ʻano he triple therapy i ka hala ʻole ʻana o ka hopena o ka hoʻohana ʻana i nā lāʻau lapaʻau e pili ana i ka insulin a me ka metformin, i hoʻohana mua ʻia, e kau ʻia ma kahi meaʻai a me ka hoʻoikaika kino kino.

Nā ʻōpala a me nā ʻano kumu o ka hoʻohana ʻana i ka lāʻau

Kahi ʻia ka ʻano o kēia lāʻau lapaʻau ka ʻokoʻa no kēlā me kēia maʻi e pili ana i ka nui o ka maʻi a me ka hoʻomanawanui i ka lāʻau o ka lāʻau. ʻO ka hāpai ʻana o Galvus i ka lā ʻaʻole e hilinaʻi i ka kō kai. Wahi a nā loiloi, a ma hope ke hana ʻana i kahi maʻi maʻi, ua kuhikuhi koke ʻia kēia lāʻau lapaʻau.

ʻO kēia lāʻau lapaʻau me monotherapy a i hui pū paha me metformin, thiazolidinedione a i ʻole insulin i lawe ʻia mai 50 a 100 mg i kēlā me kēia lā. Inā hōʻike ʻia ke ʻano o ka mea maʻi me ka ikaika a hoʻohana ʻia ka insulin e hoʻomau i ka pae o ke kō i loko o ke kino, a laila ma ka helu o kēlā me kēia lā he 100 mg.

Ke hoʻohana nei i ʻekolu mau lāʻau, no ka laʻana, vildagliptin, derivatives sulfonylurea a me ka metformin, heʻano maʻamau ka hana o kēlā me kēia lā.

Hoʻomaopopo ʻia ka nui o nā memo o ka 50 mg i ka hoʻokahi i ke kakahiaka, pono ke hoʻokaʻawale ʻia kahi hapai o 100 mg i ʻelua inikua: 50 mg i ke kakahiaka a like i ka ahiahi. Inā no kekahi kumu i hala kekahi lāʻau lapaʻau, pono e hoʻokaʻawale i ka wikiwiki, ʻoiai ʻaʻole eʻoi aku i kēlā me kēia lā i ka lā i ka lā lapaʻau.

ʻO ka maʻaʻana o kēlā me kēia lā o Galvus i ka mālamaʻana i ʻelua mau mea hou aku paha he 50 mg i kēlā me kēia lā. No ka mea i hoʻohana ʻia nā lāʻau lapaʻau i loko o ka hana paʻakikī me ka Galvus e hoʻonui i kona hopena, ʻo ka nui o kēlā me kēia lā o 50 mg e pili ana i 100 mg i kēlā me kēia lā me ka monotherapy me kēia lāʻau lapaʻau.

Inā ʻaʻole i hopena ka hopena o ka mālama ʻana, e pono e hoʻonui i ka nui i ka 100 mg i kēlā me kēia lā, a kuhikuhi pū nō hoʻi i ka metformin, sulfonylureas, thiazolidinedione a i ʻole insulin.

I nā mea maʻi me nā pilikia i ka hana ʻana o nā ʻiole kūloko, e like me nā pūpū a me ka ate, ʻo ka nui loa o ke kiʻekiʻe o Galvus e ʻole e pākuʻi i 100 mg pākahi. I ka hihia o nā hemahema koʻikoʻi i ka hana o nā keiki, ʻo ka nui o ka lā o ka lā lapaʻau e pono ʻole ma mua o 50 mg.

Nā meaʻala o kēia lāʻau lapaʻau, me kahi makana no ka pae pāʻālua ATX-4: Onglisa, Januvia. ʻO nā hui nui e pili ana i ka waiwai like ʻo Galvus Met a me Vildaglipmin.

Hoʻomaopopo ka poʻe hoʻomanawanui o kēia mau lāʻau, a me nā haʻawina e hōʻike ana i ko lākou hoʻololi i ka mālama ʻana i ka maʻi maʻi maʻi.

Nā hopena hopena

Hiki i ka hoʻohana ʻana i nā lāʻau lapaʻau a me Galvus Met ka mea e hoʻopilikia i ka hana a nā kino o ke kino a me ka mokuʻāina he ʻano holoʻokoʻa. ʻO nā hopena ʻokoʻa maʻamau i hōʻike ʻia:

kūleʻe a me ka ʻeha
haʻalulu hele lima
ka manaʻo ʻana o ke kolamu
mualū hoʻopili ʻia e ka luaʻi ʻana
gastroesophageal reflux,
ka eha a me ka ʻeha i ka ʻōpū,
pakano ʻaʻano,
nā huahuʻi, constipation a me nā maʻi o ka maʻi,
ka māla ʻana
haʻahaʻa kino kino i nā maʻi a me nā hopena,
haʻahaʻa hana haʻahaʻa a me ka luhi wikiwiki,
akeʻa a me ka maʻi pancreas, no ka laʻana, ka hepatitis a me ka pancreatitis,
ka ikaika ikaika o ka ʻili,
ke ʻano o nā huʻi.

Nā maʻi hoʻohālikelike i ka hoʻohana ʻana i ka lāʻau

ʻO nā mea kumu aʻe a me nā loiloi paha e hoʻohālike ʻia e mālama ʻia me kēia lāʻau lapaʻau.

kahi maʻi kūlohelohe a i ʻole molaki paha i nā mea ikaika o ka lāʻau,
maʻi 'ōpū, hope a me ka hana luhi
hiki i nā kūlana ke alakaʻi i nā hana ʻoi aku ka hopena, no ka laʻana, ka luaʻi, ka maʻi ʻana, ka maʻi a me nā maʻi maʻi maʻi,
nā maʻi o ka ʻōnaehana cardiovascular, ka hapa nui o ka naʻau, ka myocardial infarction,
maʻi ʻeha
maʻi ketoacidosis maʻi 'ōhele ʻia e ka maʻi, kahi coma a i kahi kūlana predomatous, me kahi hoʻopiʻi o ka maʻi maʻi. I kahi keu o kēia lāʻau, pono ka hoʻohana ʻana i ka insulin.
ka hōʻiliʻili o ka waikena lactic i loko o ke kino, lactic acidosis,
hapai a me ka umauma,
ʻo ke ʻano maʻi maʻi mua
poino waiʻona a poino waiwa,
ka pili ana i ka meaʻaiʻai paʻa, kahi hana ʻoi a pau loa ma mua o 1000:
hoʻomanawanui. ʻAʻole kuhikuhi ʻia ka koho ʻana o ka lāʻau i nā mea maʻi ma lalo o ka makahiki 18. Manaʻo ʻia nā poʻe ʻoi aku ma mua o 60 mau makahiki e lawe i ka lāʻau lapaʻau ma lalo o ka mālama ʻana o nā kauka,
pau ka lāʻau i ke hala i ʻelua mau lā ma mua o nā hana hoʻokō i hoʻonohonoho ʻia, nā hoʻokolohua radiographic a i ʻole ka hoʻomaka ʻana o ka hoʻohālikelike. Manaʻo ʻia ʻia e hōʻole i ka hoʻohana ʻana i ka lāʻau lapaʻau no 2 mau lā ma hope o nā kaʻina hana.

Mai ka wā e lawe ai iā Galvus a i Galvus Meta, ʻo kahi nui o nā contraindications he lactic acidosis, nā mea maʻi e hōʻeha nei i nā maʻi o ke akeʻa a me nā ʻōpio e hoʻohana i kēia mau lāʻau lapaʻau e mālama ai i ka maʻi diabetes type 2.

I ka poʻe maʻi i hala he 60 mau makahiki o ka nui o ka hopena o nā hoʻopiʻi o ka maʻi mellitus, ka loaʻa ʻana o ka acidosis lactic, ka mea i hoʻohui ʻia i ka māhele o ka lāʻau - metformin, hoʻonui pinepine ʻia. No laila, pono e hoʻohana pono me ka makaʻala loa.

ʻO ka hoʻohana ʻana i ka lāʻau lapaʻau i ka wā o ka wā hāpai a me ka umauma

ʻAʻole i aʻo ʻia ka hopena o ka lāʻau i nā wāhine hāpai, no laila ʻaʻole ʻia ke alakaʻi ʻana no nā wahine hāpai.

I loko o nā hihia o ka hoʻonui nui o ke koko i nā wahine hāpai, aia nō ka loaʻa ʻana o nā mau pōmaikaʻi congenital i loko o ke keiki, a me ka loaʻa ʻana o nā maʻi like ʻole a me ka make ʻana o ka ʻōpio. I nā hihia i hoʻonui ʻia i ke kō, ua ʻōlelo ʻia e hoʻohana i ka insulin e hoʻomaʻamaʻa iā ia.

Ma ke kaʻina noiʻi o ka hopena o ka lāʻau lapaʻau ma ke kino o kahi wahine hāpai, kahi dosis iʻoi aku ma mua o ka 200 manawa i hoʻolilo ʻia. I kēia hihia, ʻaʻole i ʻike ʻia kahi hala ʻole o ka hoʻomohala ʻana o ka pūpū a i ʻole nā mea hoʻonui e hoʻomaʻamaʻa ʻia. Me ka hoʻomakaʻana o ka vildagliptin i hui pū me ka metformin ma kahi hoʻohālike o ka 1:10, ʻaʻole i kākau ʻia nā kolohe i ka hoʻopuka ʻana i loko o ka ulu ʻana o ka pūpū.

Eia kekahi, ʻaʻohe mau mea hilinaʻi ma ka excretion o nā mea i mālama i ka lāʻau i ka wā o ka hoʻouluʻana me ka waiū. Ma kēia mau mea, ʻaʻole i ʻōlelo ʻia nā makuahine hānai e lawe i kēia mau lāʻau.

ʻAʻole ia e hōʻike ʻia ka hopena o ka hoʻohana ʻana i ka lāʻau ma nā kānaka ma lalo o 18 makahiki. ʻAʻole ʻike ʻia nā ʻano ʻino ʻino loa mai ka hoʻohana ʻana i ka lāʻau e nā poʻe maʻi o kēia ʻano makahiki.

Nā manaʻo loea

ʻOiai ke kūpono nei kēia mau lāʻau lapaʻau e hoʻomaʻamaʻa i ke kōpaʻa i ka diabetes type 2, ʻaʻole kēia o nā analog analog. Ke hoʻohana ʻia nei iā lākou, aʻo nā kauka i ka hoʻoholo pinepine ʻana i nā hana biochemical o ka ate.

ʻO kēia ma muli o ka vildagliptin, ʻo ia kahi o ka lāʻau lapaʻau, e alakaʻi ai i ka hoʻonui i ka hana o aminotransferases. ʻAʻole ʻike kēia ʻike i kekahi mau ʻōuli, akā ke alakaʻi nei i ka hōʻino ʻana o ka ate. Loaʻa kēia hiʻohiʻona i ka hapa nui o nā poʻe maʻi mai ka hui kaohi.

ʻO nā mea maʻi e lawe nei i kēia mau lāʻau lapaʻau no ka manawa lōʻihi a ʻaʻole hoʻohana i kā lākou analogues e noi ʻia e lawe i ke kao koko ma ka liʻiliʻi he hoʻokahi i ka makahiki. ʻO ke kumu o kēia noiʻi e maopopo ana i kekahi mau kū ʻana a i ʻole nā hopena paha ma ka papa mua a me ka hoʻohana pono ʻana i nā hana e hoʻopau ai iā lākou.

Me ka pīhoihoi kūloko, ke kaumaha, ka palaualelo, ka hopena o ka lāʻau lapaʻau ma ka mea maʻi e hiki ke hoʻemi ʻia. Hoʻomaopopo nā loiloi hoʻomanawanui i nā hopena like o ka lāʻau lapaʻau e like me ka nausea a me ka maʻi maʻi. Me kēlā mau ʻōlapa, ʻōkuhi ia e pale i ka hoʻokele a i ka hana ʻana i nā hana i hoʻonui ʻia.

Nui! ʻO 48 mau hola ma mua o kekahi ʻano maʻi a me ka hoʻohana ʻana o kahi kūʻokoʻa kūlike, e pono ai e kāpae i ka lawe ʻana i kēia mau lāʻau. ʻO kēia ke kumu o ka hoʻohālikelike ʻana o ka iodine, i ka pū me nā hua o ka lāʻau, hiki ke piʻi i ka maʻi kino i ka hana o ka aʻalā a me nā hana ate. E kūʻē i kēia kiʻi, hiki i ka mea maʻi ke hoʻomohala i ka acidosis lactic.

ʻO Galvus meth: nā loiloi maʻi maʻi maʻi, nā ʻōlelo pili no ka hoʻohana ʻana

ʻO ka lāʻau lapaʻau ʻo Galvus i ʻike ʻia no ka mālama ʻana a me ke kōkua ʻana i nā hōʻailona o ka maʻi mellitus o ka maʻi kūʻokoʻa o ka insulin. Ua hoʻomohala ka lāʻau lapaʻau hou i kahi nui o nā lāʻau like ʻole o nā hui like ʻole a me nā papa.

ʻO nā lāʻau lapaʻau e hoʻohana ai a he aha ka mea maikaʻi no nā poʻe maʻi me kēia maʻi e hōʻemi ai i ka pathology a hōʻoliʻoli i nā hopena maikaʻi ʻole e hoʻoholo ʻia e nā kauka komo e alakaʻi nei i ka maʻi o ka mea maʻi.

Ke hoʻohana nei nā lāʻau lapaʻau hou i nā ʻano like ʻole o nā lāʻau lapaʻau e hoʻokaʻawale i nā kiʻekiʻe o ka glucose a mālama i nā kaʻina metabolic i loko o ke kino.

Pono kekahi lāʻau lapaʻau e kuhikuhi ʻia e ka lāʻau lapaʻau.

I kēia hihia, mālama pilikino a i ʻole loli i ka lāʻau lapaʻau, ʻāpā kāhea kona dosage, no ka mea e hiki ke hōʻeha i nā hopena maikaʻi ʻole.

Ke paʻakikī nei me ka hoʻomohala ʻana i nā patula, pono e hoʻomanaʻo ʻia ka lawe ʻana i nā lāʻau lapaʻau me ka mālama mau ʻana i nā pae glucose koko.

I kēia lā, ʻo ka hoʻohana ʻana o ka mellitus type type 2 is the use of one of the following

ʻO ka lāʻau lapaʻau i koho ʻia no ka mālama ʻana, pono e lawe i nā kao i hōʻike ʻia e ke kauka.

Eia kekahi, ʻo ka maʻi o ka mea maʻi, ka pae o ka hana pilikino, ke kaupaona o ke kino e noʻonoʻo pono ai.

He aha ka lāʻau lapaʻau hypoglycemic?

ʻO ka lāʻau lapaʻau ʻo Galvus ka hopena he lāʻau hypoglycemic no ka hoʻoponopono waha. ʻO nā mea nui o ka lāʻau lapaʻau ka ʻelua mau mea - vildagliptin a me ka metformin hydrochloride

ʻO Vildagliptin kahi māka o nā papa o ka hoʻoulu ʻana o ka ʻahahui mahele mokupuni o ka pancreas. Kōkua ka mea e hoʻonui ai i ka hoʻololi ʻana i nā selela a me nā kō i komo mai i ke kō e hiki mai ana ka mea ua pōʻino lākou. Pono e noʻonoʻo ʻia inā i lawe ʻia kēlā mau ʻano e kahi kanaka olakino, ʻaʻohe ʻano o ke koena o ke kō.

ʻO ka Metformin hydrochloride he mea moho o ka hui biguanide o nā kolu o ka mua, ka mea i hāʻawi ʻia i ka pale ʻana o ka gluconeogenesis. Ke hoʻohana nei i ka lāʻau lapaʻau e pili ana i ka mea e hoʻoulu ai i ka glycolysis, kahi e hoʻomaikaʻi ai i ka hoʻomaikaʻi maikaʻi aʻe o ka glucose i nā puna a me nā kiko o ke kino. Eia kekahi, aia kahi wīwī i ka lawe ʻana o ka glucose i nā sela ʻeha. ʻO ka pōmaikaʻi nui o ka metformin ka mea ʻaʻole ia e lilo i ka emi o ka haʻahaʻa o ka glucose (i lalo o ke ʻano kiʻekiʻe) a ʻaʻole i alakaʻi i ka hoʻomohala a hypoglycemia.

Eia kekahi, ʻo ka hoʻonohonohoʻana o Galvus mete loaʻa i nā mea hoʻonani. Hoʻolālā pinepine ʻia nā papa like ʻole no nā maʻi me ka mellitus maʻi diabetes, no ka mea e hoʻopili maikaʻi lākou i ka lipid metabolism i loko o ke kino, a kōkua pū hoʻi i ka hoʻemi ʻana i ka nui o nā kolamu maikaʻi ʻole (hoʻonui i ke kiʻekiʻe o ka maikaʻi), triglycerides a me nā lipoproteins haʻahaʻa haʻahaʻa.

Ke hōʻike nei ka lāʻau lapaʻau i nā hōʻike aʻe nei no ka hoʻohana ʻana:

ma ke ʻano he lāʻau monotherapeutic no ka maʻi mellitus type 2, ʻoiai he mea pono ke mālama i ka ʻai iki a me ka hoʻoikaika ʻana i ke kino.
e hoʻololi i nā mea kanu Galvus Met mea ikaika
inā maikaʻi ʻole ka mālama ʻana ma hope o ka lawe ʻana i nā lāʻau lapaʻau me hoʻokahi mea ikaika - metformin a vildagliptin paha,
i ka hoʻomaʻamaʻa paʻakikī ʻana me nā ʻāpana o ka insulin a i ʻole ai paha ka olakē sulfonylurea.

Ua ʻike ʻo Galvus i nā ʻōlelo aʻoaʻo no ka hoʻohana ʻana ua paʻa ka lāʻau mai ka lumen o ka pōpoki liʻiliʻi i loko o ke koko. No laila, ua ʻike ʻia ka hopena o nā papa i loko o ka hapalua hola ma hope o kā lākou hoʻoponopono.

ʻO ka waiwai hana e hoʻopuʻi mau ʻia i ke kino holoʻokoʻa, a ma hope o ka hoʻopili ʻia ʻana me ka urine a me nā feces.

ʻO ka lāʻau Galvus lāʻau - nā ʻōlelo no ka hoʻohana ʻana, ka wehewehe ʻana, nā loiloi

I ka loaʻa ʻana o ka maʻi mellitus no ke ʻano type 2, ua hōʻike pinepine ka poʻe loea i ka lāʻau lapaʻau Galvus. Ma kahi ʻāpana o kēia lāʻau lapaʻau, ʻo ka vildagliptin ka mea nui. Aia kēia huahana i ke ʻano o nā papa. ʻO nā loiloi o nā kauka a me nā mea maʻi e pili ana i ka lāʻau lapaʻau ka nui o nā mea kūpono.

ʻO ka hopena koʻikoʻi e loaʻa i ka wā o ka lapaʻau me kēia loiloi hoʻokolohua pancreatic, a i ʻole, he mea hana ʻo ka islet. Kēia ʻano hopena e alakaʻi i ka hoʻohemo maikaʻi ʻana i ka hana o ka enzyme dipeptidyl peptidase-4. ʻO ka hōʻemi ʻana i kona hana e alakaʻi ai i ka hoʻonui ʻana i ka mea huna o ka pionide e like me ka pona o ka pona.

Ke koho ʻana i ka lāʻau lapaʻau Galvus, ʻae nā kuhikuhi no ka hoʻohana ʻana e ʻike i ka mea maʻi e ʻike i nā hōʻailona no ka hoʻohana ʻana i kēia lāʻau mālama. ʻO ka mea nui ka type diabetes 2

Ma hope o ke kūleʻa ʻana, koho ka ʻokoʻa kūikawā i kahi ʻano o nā lāʻau lapaʻau no ka mālama ʻana i ka maʻi maʻi. Ke koho nei i ka dosis o ka lāʻau, hele nui mai ia uhai o ka mai, a lawe pū i ka hoʻākāka ʻokoʻa o ka lāʻau lapaʻau.

ʻAʻole hiki ke alakaʻi ʻia ka mea maʻi e kahi pāʻina i ka wā o Galvus therapy. ʻO nā mea e pili ana i nā loiloi ʻo Galvus e hōʻike nei ma hope o ka loaʻa ʻana o ka maʻi diabetes type 2, ʻo nā mea loea mua ka mea e kuhikuhi ai i kēia lāʻau hoʻoponopono.

Ke lawe nei i ka ʻoihana paʻakikī, aia pū me ka metformin, thiazolidinedione a i ʻole insulin Galvus e lawe ʻia ana ma loko o kahi waihona ʻo 50 ka 100 mg i kēlā me kēia lā. I ka hopena i hōʻemi ʻia ke ʻano o ka mea maʻi, a laila hoʻohana ʻia ka insulin e hōʻoia i ka hoʻokū ʻana o nā waiwai o ka kō koko koko. I kēlā mau hihia, ʻaʻole pono nā mea o ka nui o ka lāʻau lapaʻau ma mua o 100 mg.

Ke kau nei ke kauka i kahi hoʻoponopono lapaʻau e pili ana i ka lawe ʻana i kekahi mau lāʻau lapaʻau, no ka laʻana, Vildagliptin, sulfonylurea derivatives a me Metformin, a laila ma kēia ke ʻano o ka papa i kēlā me kēia lā he 100 mg.

Hāpai nā poʻe loea no ka wehe maikaʻi ʻana o ka maʻi e Galvus e lawe i ka wai lāʻau o 50 mg o ka lāʻau i ka manawa hoʻokahi i ke kakahiaka. Kaukaʻi nā kauka i ke hoʻokaʻawale ʻana i ka nui o 100 mg i loko o ʻelua iniha. Pono ʻia ka 50 mg i ke kakahiaka a me ka nui o ka lāʻau lapaʻau i ke ahiahi. Inā haʻalele ka mea maʻi i ka lāʻau lapaʻau no kekahi kumu, a laila hiki ke hana ʻia kēia i ka hiki.E hoʻomaopopo, ʻaʻole i loaʻa i kahi nui i hoʻoholo ʻia e ke kauka.

Ke hōʻike ʻia kahi maʻi me nā mea ʻelua a keu paha, ʻaʻole pono ka nui o ka lā i kēlā me kēia lā he 50 mg. ʻO kēia no ka mea i ka manawa i ʻae ʻia nā mea'ē aʻe e hoʻohui i Galvus, a laila hoʻonui ʻia ka hopena o ka lāʻau nui. ^ E Ha yM. I kēlā mau hihia, he kaulia o kahi o 50 mg ka pilina me 100 mg o ka lāʻau i ka wā o ka monotherapy.

Inā ʻaʻole e hāʻawi ka mālama i ka hopena i makemake ʻia, e hoʻonui nā mea aʻoaʻo i ka nui i 100 mg i kēlā me kēia lā.

I kēlā mau maʻi e loaʻa ʻaʻole e maʻi wale nō mai ka maʻi maʻi, akā loaʻa nō hoʻi nā maʻi i ka hana o nā ʻāpana o ke kino, ka pūlima, nā ʻōpū a me nā ʻōpū, ʻo ka nui o ka lāʻau i ka ʻoihana ʻana o ka maʻi i lalo e pono ai ma mua o 100 mg i kēlā me kēia lā. Inā he hana koʻikoʻi maʻi koʻikoʻi, a laila pono ke kauka ke kuhikuhi i nā lāʻau lapaʻau ma kahi o 50 mg. ^ E Ha yM. ʻO kahi hoʻohālikelike o Galvus nā lāʻau like ʻole:

ʻO kahi analog e loaʻa ka like pū o ka pūnaehana like o ka hana ʻo Galvus Met. Me ia mea, kuhikuhi pinepine nā kauka iā Vildaglipmin.

Ke kuhikuhi ʻia nei ka lāʻau lapaʻau no ka mālama ʻana, ʻo Galvus Met, a laila lawe ʻia ka lāʻau lapaʻau me ka maʻi maʻamau, a pono pono e inu i ka lāʻau lapaʻau me ka nui o ka wai. Koho ʻia ka nui o ka maʻi no kēlā me kēia maʻi e ke kauka. I kēia hihia, pono e mālama i ka ʻoiaʻiʻo o ka nui ʻaʻole pono nā dosage i ka 100 mg.

I ka hoʻomaka ʻana o nā lāʻau lapaʻau me kēia lāʻau lapaʻau, ua hoʻākāka ʻia ke ʻano e ka ʻimi ʻana iā Vildagliptin a me Metformin. I mea e hoʻopau ʻia ai nā hiʻohiʻona maikaʻi o ka ʻōnaehana o ka hana ʻana i ka wā o ka mālama ʻana, pono ka lawe ʻana i kēia lāʻau me ka meaʻai.

Inā hāʻawi ʻo ka mālama iā Vildagliptin i ka hopena i makemake ʻia, a laila ma kēia hihia hiki iā ʻoe ke kuhikuhi me ke ʻano o ka lāʻau Galvus Met. ^ E Ha yM. I ka hoʻomakaʻana o ke papa o ka lāʻau, pono kahi maʻi o 50 mg 2 mau manawa i kahi lā. Ma hope o kahi manawa pōkole, hiki ke hoʻonui ʻia ka nui o nā lāʻau lapaʻau no ka loaʻa ʻana o ka ikaika.

Inā ʻaʻole i ʻae ʻia ka mālama ʻana me Metformin e hoʻokō pono i kahi hopena maikaʻi, a laila e noʻonoʻo pono i ka ʻano lāʻau i kauoha ʻia i ka wā e hoʻokomo ai ʻo Glavus Met i ka regimen mālama. ʻO ka hopena o kēia lāʻau lapaʻau e pili ana i ka Metoformin hiki iā 50 mg / 500 mg, 50 mg / 850 mg a i 50 mg / 1000 mg. Pono ka māhele o ka lāʻau lapaʻau e hoʻokaʻawale i 2 mau dosis. Inā koho ʻia ʻo Vildagliptin a me Metformin i loko o ke ʻano o nā papa i koho ʻia no ke ʻano kumu o ka lāʻau, a laila ua ʻōlelo hou ʻia ʻo Galvus Met, kahi mea e lawe ʻia ma kahi o 50 mg i kēlā me kēia lā.

ʻAʻole pono e hāʻawi ʻia i ka mea maʻi me kēia mea maʻi i nā mea maʻi ʻole. hana ʻole i loko o ka pilikia. ^ E Ha yM. ʻO kēia contraindication ma muli o ka loaʻaʻana o ka lāʻau ikaika o kēia lāʻau lapaʻau mai ke kino e hoʻohana ai i nā keiki. Me ka nui o ka makahiki, e hoʻohaʻahaʻa ka hana a nā kānaka. Hiki pinepine kēia i nā mea maʻi i hala i nā makahiki 65 o ka makahiki.

No ka poʻe maʻi i kēia makahiki, ua kuhikuhi ʻia ʻo Galvus Met ma ka palena liʻiliʻi loa, a hiki ke hoʻokaʻa ʻia nei ke ʻano o kēia lāʻau ma hope o ka loaʻa ʻana o ka hōʻoia ke hana mau nā maʻi o ka maʻi. I ka wā e mālama ai, pono e mālama pinepine ke kauka i kā lākou hana.

I nā ʻōlelo e pili ana i ka hoʻohana ʻana, ʻo ka mea hana i ka lāʻau Galvus Met e hōʻike ana i ka hoʻokomo o kēia lāʻau lapaʻau e hiki ke hoʻopilikia i ka hana o nā ʻāpana kūwaliwali a pōʻino i ke kūlana o ke kino holoʻokoʻa. I ka manawa pinepine, loaʻa i nā maʻi e hahai ana i nā hōʻailona leʻaleʻa a me nā kūlana no ka mālama ʻana i kēia lāʻau lapaʻau:

mea ʻalaʻawa
ka ʻeha ʻeha o ka ʻōpū
ke hiʻohiʻona o nā polū alamo i ka ʻili,
maʻi gastrointestinal pilikia i loko o ke ʻano o ka constipation a me ke kūʻī,
ke ʻano kūlana
kaemi ʻana i ke kino o ke kino i nā maʻi,
ke ʻano o kahi kūlana o ka ʻili o ka ʻili,
ke kūmole i ka ʻili o nā ʻōmaka.

Ma mua o ka hoʻomaka ʻana i ka maʻi me kēia lāʻau lapaʻau, pono ia e familiarize iā ʻoe iho me nā contraindications e hiki ke loaʻa i nā ʻōlelo kuhikuhi no Galvus. Eia ka mea penei:

ka hele ʻana o kahi hopena a alia ʻole e pili ana i nā ʻāpana o ka lāʻau lapaʻau,
ka hiki ʻana o kahi maʻi o ka ʻōpū, ka hana ʻole ʻole a i ʻole ke hōʻino i kā lākou hana,
ke kūlana o ka mea maʻi, kahi e hiki ai ke hoʻonāukiuki i ke ʻano o kahi hana renal impaired,
maʻi maʻi
maʻi ʻeha
ka ʻohi ʻana o ke kino o ka mea maʻi i ka nui o ka waika o ka lactic,
inu awaakou, inu hewa,
ka mea eʻai ai nā meaʻai ma kahi o ka calorie o nā meaʻai ʻaʻole iʻoi aku ma mua o 1000 kalona i kēlā me kēia lā,
hoʻomanawanui. ʻAʻole kuhikuhi nā kauka i nā lāʻau lapaʻau i nā poʻe i hiki ʻole i ka makahiki 18. No ka poʻe maʻi o ʻoi aku o 60 makahiki o kona mau makahiki, pono ʻia kēia lāʻau lapaʻau e kiaʻi ma lalo o ka mākaʻi paʻa ʻana e ke kauka hele mai.

I koʻu hōʻike ʻana i ka maʻi maʻi, ua kuhikuhi ke kauka iaʻu i nā papa papa ʻo Galvus Met. Hoʻomaka e lawe i kēia lāʻau, ua kū koke au me nā hopena ʻaoʻao. ʻO ka pilikia mua i hiki mai iaʻu ʻo ka hōʻeu ʻana o ka wāwae o ka wāwae. Eia naʻe ma hope o kekahi manawa, ua hala nā mea a pau. Lawe au i ka maʻi piha o ke kau lāʻau i ke kakahiaka. Noʻu, he kūpono loa kēia ma mua o ka hoʻokaʻawale ʻana i ka maʻa i nā inikua ʻelua. Me ka hoʻomanaʻo, eia koʻu mau pilikia i kekahi manawa a hoʻopoina wau i ka inu ʻana i kahi pōʻai i ke ahiahi.

ʻO ka maʻi maʻi āpau 2 ka maʻi he paʻakikī nui e hoʻowalewale ʻia. ʻO kēia maʻi ua nui nā hōʻailona implicit e hiki i nā mea a pau ke aʻo e pili ana i ka Pūnaewele. ʻO Galvus Met no ka mālama ʻana i kēia maʻi ua hōʻike ʻia iaʻu e ke kauka ma hope o ka hoʻopaʻa ʻana i ka maʻi. Makemake wau e hoʻomaopopo koke i ke kumu o ka hāmeʻa o kēia pono hana. Ke heluhelu nei i kahi loiloi e pili ana i kēia lāʻau lapaʻau, ʻike pinepine wau i kahi ʻōlelo e pili ana i kēia minuke.

No ka mālama ʻana i koʻu maʻi, ua kūʻai aku au i ka lāʻau i loko o kekahi o nā mākeke, kahi i ʻoi aku kēia lāʻau ma mua. ʻO ka hana nui ma Galvus ʻo ia, ʻaʻole e like me nā analogues, he kūlike loa kēia hāmeʻa. ʻAʻole kēia ʻo ka manawa mua kaʻu i lawe ai i ka lāʻau lapaʻau, ʻaʻole hoʻi i loaʻa iaʻu ka hopena maikaʻi loa no ka loaʻa ʻana o ka maʻi mellitus. Makemake wau e aʻo iā ia i kekahi i ʻike i kēlā maʻi ʻino. I mea e ola ai ka hoʻomaʻemaʻe ʻana, pono ʻoe e poina e pili ana i kahi papaʻai koʻikoʻi, me ia hoʻi e hoʻohui i ke kino pilikino i kāu papa maʻamau.

Me ka monotherapy diabetes, hiki iā ʻoe ke hoʻohana i ka Galvus Met a hoʻohana ʻole i kēia lāʻau lapaʻau i loko o kahi hoʻoponopono lapaʻau hui hoʻohui. Makemake wau e ʻike i ka hoʻoholo ʻana no ke koho ʻana i ka lāʻau lapaʻau e pono ke hana i ka kauka kauka hele wale nō. ʻO koʻu makuahine, ke ʻeha nei i ka maʻi maʻi, ʻaʻole kūpono ke ʻano o ka mālama ʻana. Aia kekahi mau hopena leʻaleʻa - ua hoʻokumu ʻia kahi ulia ʻōpū. Ua ʻoi aku kona maʻalahi ma Galvus ma mua o ke hui pū me nā ʻano ʻē aʻe. Akā naʻe, makemake wau e hoʻomaopopo ka ʻokoʻa o ka hopena i kēia lāʻau lapaʻau no kēlā me kēia kanaka.

I ka wā o ka mālama ʻana me kēia lāʻau lapaʻau, loaʻa mai ka hopena o ka lawe ʻana o ke kaumaha, he mea nui loa ia no nā mea maʻi me ka maʻi maʻi. Akā mālama i ka lāʻau lapaʻau ma loko o kahi waihona o 50 mg ʻaʻole i alakaʻi i ka emi ʻana o ke kaumaha o ke kino. Eia naʻe, ʻoi aku ka hopena o ka ʻōpū ma mua o ke ʻano. ʻO kēia lāʻau lapaʻau kahi papa inoa o nā contraindications e pono ai ʻoe e ʻike ma mua. He mea koʻikoʻi loa kēia no nā poʻe e loaʻa nei i ka maʻi kīpē a i ʻole ka pilikia kō.

Ke ulu mau nei ka nui o ka poʻe me ka maʻi diabetes. Ma hope o kahi hōʻike maʻi, ʻike pinepine nā kauka i ka lāʻau Galvus, ma waena o nā lāʻau āpau i manaʻo ʻia no ka mālamaʻana i ka maʻi maʻi, ʻo kekahi o nā mea nui loa. ^ E Ha yM. Pono e ʻōlelo ʻia hiki i kēia lāʻau lapaʻau ke hoʻokaʻawale a me ke ʻāpana o ka hui pū ʻana e hui pū me nā mea hana ʻē aʻe i loaʻa i ka insulin. Eia naʻe, ʻo ke kauka komo hele wale nō i kuleana e kuhikuhi i kahi lāʻau lapaʻau.

ʻO ka hoʻohanaʻana i kēia lāʻau lapaʻau i kahi hopena i hoʻoholo ʻia e ke kauka e hiki ai iā ʻoe ke hoʻokau i nā hōʻailona o ka maʻi. Eia naʻe, no ka hoʻokō i ka hopena i makemake ʻia, pono e hahai i nā ʻōmole a pau o ka loea, a he mea ʻē aʻe i kēia, pili i kahi meaʻai a hoʻokomo i ka hana kino i kāu hana maʻamau. I kēia hihia, e hoʻonui nui ʻia ka hoʻouka ʻana o ka lāʻau.

Pono kēlā me kēlā me kēia maʻi e pili ana i nā contraindications i loaʻa i ka lāʻau Galvus ma mua o ka hoʻomaʻamaʻa. ^ E Ha yM. Ma hope o 65 mau makahiki, e pono ke kuhikuhi i kēia lāʻau lapaʻau me ka mālama nui loa. Hoʻopili ʻia nā mea nui o ka lāʻau e nā ʻōpū, no laila, ʻaʻohe hewa kekahi ma kā lākou hana.

I nā makahiki he ʻelemakule, hoʻemi ka hana o nā keiki, no laila, i ka manawa e kuhikuhi ana i nā lāʻau lapaʻau i kēlā mau mea maʻi, pono ke kiaʻi mau ke kauka hele i ka hana o nā keiki. Pono e hoʻomaopopo pono ʻoe ʻo ka hoʻohana ʻana i ka waiʻona ma loko o kahi nui he contraindication i ke kau ʻana o kēia ʻōnaehana.

ʻAʻole loa i loko o nā lāʻau lapaʻau hiki iāʻoe ke loaʻa i ka lāʻau Galvus no ka mālamaʻana i ka maʻi maʻi. Akā, maʻalahi ka pilikia o kēia pilikia ma muli o ka hiki i loko o kahi pūnaewele lapaʻau he helu nui o nā kūmole. ^ E Ha yM. ʻO kahi ākea ākea o nā huahana koho e hiki i nā mea āpau ke koho i kahi huahana, me ka noʻonoʻo ʻana i kona kūpono a me nā kumu kūʻai.

Ke hoʻohana nei i kahi analogue e hiki ai iā ʻoe ke hoʻopilikia i ka hoʻōla o ka lāʻau a hoʻoiho i nā maʻi i kū i ka wikiwiki. Ma mua o ke koho ʻana i kahi lāʻau lapaʻau kūikawā, pono ʻoe e heluhelu i nā loiloi e pili ana i ka lāʻau lapaʻau. Hiki iā ʻoe ka ʻike i ka nui o ka ʻike ma loko.

Nā hōʻikeʻike e pili ana i ka lāʻau lapaʻau piha nā pono e pili ana i ka hopena o ka lāʻau lapaʻau, nā hopena kūpono a me nā nuances o ka hoʻohana. Ke nānā ʻana i kēlā ʻike, hiki iā ʻoe ke koho i ka hoʻoponopono kūpono, pale aku i nā wahi maikaʻi ʻole no kou olakino a hōʻoluʻolu maʻalahi i ka maʻi i kū mai.

ʻO kahi Galvus Met kahi lāʻau lapaʻau kūpono no nā maʻi maʻi type 2, kahi mea kaulana loa, ʻoiai ke kumukūʻai kiʻekiʻe.

A hoʻohaʻahaʻa ia i ke kō kō koko koko a paʻa pinepine nā hopena. ʻO nā mea ikaika o ka lāʻau hui pū ʻia e vildagliptin a me ka metformin.

Ma kēia ʻaoʻao ʻike ʻoe i nā ʻikepili a pau e pili ana iā Galvus Met: kūmua ʻōlelo piha no ka hoʻohana ʻana i kēia lāʻau lapaʻau, nā kumukūʻai kumukūʻai i nā lāʻau lapaʻau, hoʻopau hou a me nā mea kikoʻī o ka laikini, me nā loiloi o ka poʻe i hoʻohana mua iā Galvus Met. Makemake e haʻalele i kou manaʻo? E ʻoluʻolu e kākau ma nā ʻōlelo.

ʻO ka lāʻau lapaʻau hypoglycemic oral.

Hoʻokuʻu ʻia ma ka papa inoa.

Ehia nā kumukūʻai o Galvus Met? ʻO ka kumukūʻai kumukūʻai i nā lāʻau lapaʻau ma ka pae o 1,600 rubles.

ʻO nā ʻano helu o ka hoʻokuʻu ʻana o Galvus Met - nā pani ʻoniʻoni kiʻi: oval, me nā kihi beveled, hōʻailona ʻo NVR ma kahi ʻaoʻao, 50 + 500 mg - ke kukui melemele me kahi hihelena pink, ʻo LLO ka hōʻailona ma ka ʻaoʻao ʻē aʻe, 50 + 850 mg - melemele me kahi hina hina hina, ʻo ka mākaʻina ma kekahi ʻaoʻao ʻo SEH, 50 + 1000 mg ʻeleʻele me ka ulaula hina, hōʻailona ʻia ma kēlā ʻaoʻao ʻē aʻe ʻo FLO (i loko o nā blagō he 6 a 10 paha., i ka pūlima kāleka 1, 3. 5, 6, 12, 18 a 36 mau blisters).

1 papa o 50 mg / 850 mg mau mea he 50 mg o vildagliptin a me 850 mg o ka metformin hydrochloride,
1 papa o 50 mg / 1000 mg he 50 mg o vildagliptin a me 1000 mg o ka metformin hydrochloride,

Nā mea kū'ē: hydroxypropylcellulose, magnesium stearate, hypromellose, titanium dioxide (E 171), polyethylene glycol, talc, ka hao hao oxide (E 172).

ʻO ka pūnaehana o ka lāʻau Galvus Met ka mea komo 2 mau mākia hypoglycemic me nā ʻano hana like ʻole: vildagliptin, no ka papa o ka dipeptidyl peptidase-4 inhibitors (DPP-4), a me metformin (i ke ʻano o ka hydrochloride) - he mākaukau o ka papa biguanide. ʻO ka hoʻohui ʻana o kēia mau mea e hiki ai iā ʻoe ke hoʻomalu hou aku i ka kaila o ke koko i ka poʻe maʻi me nā maʻi type 2 no 24 mau hola.

Hōʻike ʻia ka loaʻa ʻana o Galvus Meta i nā pilikia aʻe:

me ka maʻi diabetes type 2, ke pau ʻole nā koho lapaʻau ʻē aʻe,
i ka hihia o ka launa ʻole pono me ka metformin a vildagliptin e like me nā mea hoʻokaʻawale,
i ka mea i hoʻohana mua ka mea maʻi i nā lāʻau lapaʻau me nā ʻāpana like,
no ka mālama paʻakikī ʻana i ka maʻi lolo me nā lālani hypoglycemic a i ʻole insulin.

Ua hōʻike ʻia ka lāʻau lapaʻau i nā maʻi maʻi maʻi i loaʻa ʻole nā maʻi koʻikoʻi a me nā pilikia olakino.

ʻAʻole ia e hōʻike ʻia e lawe iā Galvus Met:

ʻO nā poʻe e kānalua nei i ka vildagliptin a i ʻole nā mea i hana ʻia nā papa.
ʻO nā ʻōpio ma lalo o ka makahiki o ka hapa nui. ʻO kahi hōʻike e like me ka mea i hōʻike ʻole ʻia ka hopena o ka lāʻau i nā keiki.
ʻO ka poʻe maʻi me ka pīhoihoi koʻikoʻi a me ka hana pūpū. ʻO kēia ma muli o ka loaʻaʻana o nā mea ikaika i ka lāʻau lapaʻau ke alakaʻi i kahi holoʻokoʻa o kēia mau kino.
Poʻe i hiki i ka wā kahiko. Ua hoʻopau ʻia ko lākou kino e hoʻolaha i nā ukana ʻē aʻe, e hana ana i nā mea e kū ana i ka galvus.
Nā wahine hāpai a me nā makuahine hānai. Pili nā ʻōlelo manaʻo i ka mea i hōʻike ʻole ʻia ka hopena o ka organism o kēia ʻano o nā maʻi i ka lāʻau lapaʻau. Aia kekahi aiaʻeʻi o nā mea hoʻonāukiuki i ka hopena o ka glucose, ka mea i hiki mai i nā mea hoʻonui mau a me ka make mau o nā pēpē.

I ka manawa e loaʻa ai ka nui o ka ʻawaʻawa i ke ana i ka lāʻau lapaʻau, ʻaʻohe ʻike hewa i ke olakino e nānā i ka poʻe.

ʻAʻole lawa nā ikepili ma ka hoʻohana ʻana iā Galvusmet i nā wahine hāpai. Ua hōʻike ʻia nā haʻawina holoholona o vildagliptin i ka hoʻopalike maʻi reproduction i nā dosis kiʻekiʻe. I nā haʻawina holoholona o metformin, ʻaʻole i hōʻike ʻia kēia hopena. ʻAʻole hōʻike ʻia nā haʻawina o ka hoʻohana ʻana i nā holoholona i ka teratogenicity, akā ua ʻike ʻia ka fetotoxicity i nā pona i nā mea make i ka wahine. ʻAʻole maopopo ka paha kūpono i loko o ke kanaka. ʻAʻole pono e hoʻohana ʻia ʻo G alvusmet i ka wā hāpai.

ʻAʻole ʻike ʻia inā hele ka vildagliptin a me / a i ʻike ʻia i ka metformin i ka waiū kanaka, no laila ʻaʻole pono e kuhikuhi ʻia ʻo G alvusmet i nā wahine i ka wā o ka ʻōpū.

ʻO nā haʻawina o vildagliptin i loko o nā lālani like me nā manawa he 200 i ka manawa o ka nui o ke kanaka ʻaʻole i hōʻike i ka nui o ka ulu ʻana a me ka hoʻolālā ʻana o ka embryonic. ʻAʻole i hana ʻia nā haʻawina o ka hopena o Galvusmet i ka ulu kanaka.

Hōʻike nā ʻōlelo no ka hoʻohana ʻana e hoʻohana ʻia ʻo Galvus Met i loko. Pono ke koho ʻia o ka hoʻoponopono ʻia no ka hoʻokahi maʻi ma muli o ka hopena a me ka hoʻohaʻahaʻa ʻana o ka lāʻau. Ke hoʻohana nei iā Galvus Met, ʻaʻole iʻoi aku ma kahi o ka nui o ka lā i ʻōlelo ʻia no ka vildagliptin (100 mg).

Pono e koho ʻia ka ʻōlelo paʻa o ka ʻōlelo ʻo Galvus Met e lawe ana i ka lōʻihi o ka maʻi diabetes a me ka pae o ka glycemia, ke ʻano o ka mea maʻi a me ka hoʻoponopono ʻia ʻana o ka vildagliptin a me / a me ke metformin i hoʻohana mua i ka mea maʻi. No ka hoʻēmiʻana i ka paʻakikī o nā hopena ʻaoʻao mai nā kino o ka gastrointestinal tract ʻano ʻano o ka metformin, lawe ʻia ʻo Galvus Met me ka meaʻai.

ʻO ka ʻōlelo mua o ka lāʻau Galvus Met me ka loaʻa ʻole o ka monotherapy me vildagliptin:

Hiki ke hoʻomaka me ka ʻoihana ʻo Galvus Met me kahi papa hoʻokahi me kahi dosis o 50 mg + 500 mg 2 mau manawa i ka lā, ma hope o ka loiloi ʻana i ka hopena therapeutic, hiki ke hoʻonui mālie ʻia ke ʻano.

ʻO ka ʻōlelo mua o ka lāʻau Galvus Met me ka hiki ʻole o ka monotherapy me metformin:

Aia ma muli o ka hāmeʻa o ka metformin i lawe ʻia, mālama ʻia me Galvus Met i hiki ke hoʻomaka me kahi papa hoʻokahi me kahi ala o 50 mg + 500 mg, 50 mg + 850 mg a 50 mg + 1000 mg 2 mau lā / lā.

ʻO ka hoʻohālikelike mua o Galvus Met i loko o nā poʻe maʻi i loaʻa i ka lāʻau hui hoʻohui me vildagliptin a me ka metformin ma ke ʻano o nā papa i ʻokoʻa.

ʻO ka hiʻona ʻana o ka vildagliptin a i ʻole ka metformin i lawe ʻia, mālama ʻia ʻo Galvus Met me kahi papa e like kokoke loa i ka ʻimi ʻana i ka hoʻōla ʻana, 50 mg + 500 mg, 50 mg + 850 mg a 50 mg + 1000 mg, a e hoʻoponopono i ka ʻolopolo i hilinaʻi ʻia. mai ka hana pono.

ʻO ka hoʻomaka ʻana o ka lāʻau lapaʻau ʻo Galvus Met ma ke ʻano he hana mua i ka poʻe maʻi me ka diabetes mellitus type 2 me ka lawa ʻole o ka hoʻoulu ʻana i ka papa ʻaina meaʻai a me ka hoʻomaʻamaʻa ʻana:

E hoʻomaka ana ka lāʻau lapaʻau, pono e hoʻohana ʻia ka lāʻau Galvus Met i kahi ma mua o ka 50 mg + 500 mg 1 manawa / lā, a ma hope o ka loiloi ʻana i ka hopena therapeutic, e piʻi mālie ka nui o ka dosis i 50 mg + 1000 mg 2 mau lā / lā.

Hoʻohui hui me Galvus Met a me nā derivatives o sulfonylurea a i ʻole insulin:

ʻO ka make ʻana o Galvus Met e helu ʻia ma ke kumu o ka maʻi o ka vildagliptin 50 mg x 2 mau manawa / lā (100 mg i kēlā lā) a me ka metformin i loko o kahi pane e like me ia ma mua o ka lāʻau hoʻokahi.

Hoʻokuʻu ʻia ka Metformin e nā keiki. Ma muli o nā mea maʻi ma mua o 65 mau makahiki he nui ka hana i ka hana o ka ʻalā, pono ke hoʻoponopono ʻia ka nui o Galvus Met ma kēia mau maʻi e pili ana i nā māka o ka hana renal. Ke hoʻohana nei i ka lāʻau lapaʻau i nā mea maʻi ma mua o 65 mau makahiki he mea pono ia, e nānā mau i ka hana renal.

ka eha a me ka ʻeha i ka ʻōpū,
pakano ʻaʻano,
nā huahuʻi, constipation a me nā maʻi o ka maʻi,
ka māla ʻana
kūleʻe a me ka ʻeha
haʻalulu hele lima
ka manaʻo ʻana o ke kolamu
mualū hoʻopili ʻia e ka luaʻi ʻana
akeʻa a me ka maʻi pancreas, no ka laʻana, ka hepatitis a me ka pancreatitis,
ka ikaika ikaika o ka ʻili,
gastroesophageal reflux,
haʻahaʻa kino kino i nā maʻi a me nā hopena,
haʻahaʻa hana haʻahaʻa a me ka luhi wikiwiki,
ke ʻano o nā huʻi.

Me ka nui o ka nui o ka lāʻau lapaʻau i hōʻike ʻia ai i ka lāʻau, nausea, luaʻi, hōʻeha ʻana i ka naʻau nui, hypoglycemia a me ka lactic acidosis (ʻo ka hopena o ka hopena o ka metformin) hiki ke ʻike. I ia mau hanana, e pau ka lāʻau lapaʻau, ka ʻeha o ka ʻōpū, ka ʻopa a me ka ʻomaʻamaʻa hōʻailona.

ʻO ʻoe e hoʻāʻo e kū i kahi inikini insulin me Galvus a i ʻole Galvus Met. Manaʻo ʻia e lawe i nā hoʻokolohua koko e nānā i ka hana o nā pūpū a me nā ate, ma mua o ka hoʻomaka ʻana i ka mālama ʻana me kēia mau mea. E hana hou i nā hōʻike i hoʻokahi manawa a ʻoi aku paha. Pono e hoʻopau ʻo Metformin i nā hola 48 ma mua o ka hoʻokō a i ʻole loiloi X-ray me ka hoʻomaka ʻana o kahi ʻāpana kūʻokoʻa.

Lele pili ʻo Vildagliptin i nā lāʻau lapaʻau ʻē aʻe.

Hiki i ka metformin ke hoʻopili me nā lāʻau lapaʻau kaulana he nui, i ka nui o nā pilina koko kiʻekiʻe a me nā hormone thyroid. E kamaʻilio me kāu kauka! E haʻi iā ia e pili ana i nā lāʻau lapaʻau a pau āu e lawe ai ma mua o ka hōʻike ʻia ʻana o ka lāʻau mālama maʻi maʻi.

Ua ʻohi mākou i kekahi o nā loiloi o ka poʻe e pili ana i ka lāʻau lapaʻau.

Inā mākou e hoʻohālikelike i ka haku mele a me nā hopena o ka mālama ʻana, a laila e like me nā mea ikaika a me ka therapeutic effective, hiki i nā analogues.

Ma mua o ka hoʻohana ʻana i ka analogue, e nīnau aku i kāu kauka.

E mālama i kahi ma kahi maloʻo a hiki i 30 ° C. Mai mālama i nā keiki.

Pehea e aʻo ai e ola me ka maʻi diabetes. - M .: Interprax, 1991 .-- 112 p.
Nā maʻi diagnostics hoʻokolohua. - M.: MEDpress-hoʻomaopopo, 2005. - 704 p.
Kruglov Victor Diabetes mellitus, Eksmo -, 2010. - 160 c.

E haʻi iaʻu iaʻu. ʻO Elena koʻu inoa. Ua hana wau ma ka endocrinologist ma mua o 10 mau makahiki. Ke manaʻoʻiʻo nei wau he kanaka mākeke wau i kaʻu kahua a makemake wau e kōkua i nā malihini a pau i ka pūnaewele e hoʻonā i nā paʻakikī a ʻaʻole pēlā nā hana. ʻO nā ʻikepili a pau no ka pūnaewele e hōʻiliʻili a hoʻomaʻamaʻa maikaʻi i mea e hōʻike ʻia e like me nā mea e pono ai ka ʻike. Ma mua o ka hoʻopili ʻana i ka mea i hōʻike ʻia ma ka pūnaewele, he kūkākūkā mandatory me nā mea loea.

E hoʻokuʻu i ke ʻano a me ka ʻano

Nā mea hoʻohana i ka papa pā 1:

vildagliptin - 50 mg,
metformin hydrochloride - 500, 850 a i ʻole 1000 mg.

Nā mea kōkua (50 + 500 mg / 50 + 850 mg / 50 + 1000 mg): hypromellose - 12.858 / 18.58 / 20 mg, talc - 1.283 / 1.86 / 2 mg, macrogol 4000 - 1.283 / 1.86 / 2 mg, hyprolose - 49.5 / 84.15 / 99 mg, stearate magnesium - 6.5 / 9.85 / 11 mg, titanium dioxide (E171) - 2.36 / 2.9 / 2.2 mg, oxide hao ʻaila hao (E172) - 0,006 / 0/0 mg, ka hao kele a ka hao (E172) - 0.21 / 0.82 / 1.8 mg.

Lapaʻau lāʻau

ʻO ka pūnaʻina o Galvus Met e loaʻa i nā mea hana ʻelua e ʻokoʻa i nā ʻano hana o ka hana: metformin (i ke ʻano o ka hydrochloride), nona nā ʻano o biguanides, a me vildagliptin, he mea lawe ia i ka peptidyl peptidase-4 (DPP-4). Hāʻawi ka hui ʻana o kēia mau mea i kahi mana i ʻoi aku ka maikaʻi o ka kaohi ʻana o ka glucose i loko o ke koko i nā mea maʻi me ka maʻi type 2 no ka lā 1.

ʻO Vildagliptin kahi kumu o ka papa o nā mea hoʻoulu ʻia o ka insular apparatus o ka pancreas, ka mea e hōʻoia ai i ka hoʻohaʻahaʻa koho i ka enzyme DPP-4, nona ke kuleana no ka luku ʻana i ka glucagon like-peptide type 1 (GLP-1) a me ka glucose-dependantine insulinotropic polypeptide (HIP).

Hoʻomau ʻo Metformin i ka hana ʻana o ka glucose i ka ʻāʻī, hōʻemi i ka pale ʻana i ka insulin ma muli o ka huki ʻana a me ka hoʻohana ʻana o ka glucose i nā kōpili peripheral, a pale i nā kao o ka glucose i loko o nā ʻāpana. He inducer kekahi o ka synthlous glycogen intracellular ma muli o kona hopena ma ka glycogen synthetase a hoʻonoho i ka hoʻoheheʻe glucose, kahi nona nā glucose transporter kūmole (GLUT-1 a me GLUT-4) ke kuleana.

Vildagliptin

Ma hope o ka lawe i ka vildagliptin, hoʻoneʻe pinepine ka hana o DPP-4 a kokoke loa, ke alakaʻi nei ia i ka hoʻonui ʻana i ka ʻai o ka ʻai a me nā mea huna o HIP a me GLP-1, kahi i hūnā ʻia mai ka ʻōpū i loko o ka ʻōnaehana ma waena o 24 mau hola.

ʻO ka hoʻonui nui o ka HIP a me GLP-1, ma muli o ka hana a vildagliptin, e hoʻonui ai i ka ʻike ʻana o ka pancreatic β-cells i ka glucose, e hoʻomaikaʻi hou ana i ka hana glucose-hilinaʻi o ka insulin. ʻO ka pae kiʻekiʻe o ka hoʻomaikaʻi ʻana i ka hana β-cell e hoʻoholo e ka pae o ko lākou hōʻeha mua. No laila, i nā poʻe i ʻole e loaʻa i ka maʻi diabetes (me ka glucose glucose maʻamau), ʻo ka vildagliptin, ʻaʻole ia e hoʻōla i ka hana o ka insulin a ʻaʻole e hōʻemi i ka glucose.

Hoʻonui ka Vildagliptin i ka kaohi o ka endogenous GLP-1, a laila e hoʻonui ai i ka ʻike ʻana o nā seleka-aʻi o ka glucose, e kōkua ana i ka hoʻomaikaʻi ʻana i ka hoʻoponopono glucose-hilinaʻi. ʻO ka emi ʻana o nā kiʻekiʻe o ka glucagon ma hope o ka papaʻaina, ma ka huli ʻana, ke alakaʻi nei i ka emi ʻana o ka pale ʻana i ka insulin.

ʻO ka hoʻonui nui aʻe o ka ratio insulin / glucagon e pili ana i ka mua o ka hyperglycemia e pili ana me ka piʻi nui o ka neʻe ʻana o ka HIP a me GLP-1 e hōʻemi ana i ka synthesis o ka glucose, ma ka wā a ma hope o ka ʻaina. ʻO ka hopena ka hopena o ka glucose glucose.

Eia nō hoʻi, i ka wā i mālama ai me ka vildagliptin, ua nānā ʻia kahi hōʻemi i nā lipid plasma ma hope o ka ʻai ʻana, akā naʻe, ʻaʻole pili kēia hopena i ka hana a Galvus Met ma HIP a ʻo GLP-1 a me ka hoʻomaikaʻi ʻana i ka hana o nā selela islet i hoʻopaʻa ʻia i ka pancreas. Aia ma laila he hōʻike nō ka hoʻonui ʻana i ka GLP-1 e kāohi i ka ʻohi ʻana i ka ʻōpū, akā ʻaʻole i nānā ʻia kēia hopena i ka wā o ka hoʻohana ʻana o vildagliptin.

Ua hōʻike ʻia nā hopena o nā haʻawina ma kahi 5759 nā mea maʻi me ka maʻi type type 2 i ka wā e lawe ai i ka vildagliptin ma ke ʻano he monotherapy a i hui pū ʻia me ka insulin, metformin, thiazolidinedione a i ʻole o ka deronone o sulfonylurea no 52 mau pule, he nui ka lōʻihi o ka hoʻohaʻahaʻa i nā pae glycated i ʻike ʻia i nā mea maʻi hemoglobin (HbA₁_C) a me ka hookeai koko i ke koko.

Hoʻonui ka Metformin i ka hoʻohaʻahaʻa glucose i nā maʻi me ka diabetes mellitus type 2, e hoʻemi ana i ka pae glucose glucose ma mua a ma hope o ka ʻai. ʻOkoʻa ka mea kū i ka derony o sulfonylurea no ka mea ʻaʻole ia e hoʻonāukiuki i ka hypoglycemia ʻaʻole i nā poʻe olakino (ʻaʻole i nā hihia kūikawā) ʻaʻole i nā mea maʻi me ka diabetes mellitus type 2. ʻAʻole mālama ʻia ka lāʻau Metformin e ka hoʻomohala ʻana o ka hyperinsulinemia. Ke lawe nei i ka metformin, ʻaʻole i loli ka hana o ka insulin, ʻoiai e emi ana ka ʻike ʻana i ka plasma koko ma mua o ka ʻaina a i ka lā a pau.

Hoʻohana maikaʻi ka hoʻohana ʻana o ka metformin i ka hana o ka lipoproteins a ke alakaʻi nei i ka hōʻemi o ka kolamu e pili ana i nā lipoproteins density haʻahaʻa, huehue ka kolamu a me nā triglycerides, ʻaʻole i pili pū me ka hopena o ka lāʻau lapaʻau ma ka pae glucose o ke koko.

Nā ʻōkuhi no ka hoʻohana ʻana iā Galvus Met: ʻano a me ka helu ʻana

Lawe ʻia nā papa papa o Galvus Metally, ʻoi aku ka maikaʻi me ka hoʻopiʻi ʻana i ka meaʻai (i mea e hoʻemi ai i ka nui o nā hopena maikaʻi loa mai ka kūnaʻi ʻana, ʻo ia ka mea o ka metformin).

Koho ʻia ka nui o ka dosimen e ke kauka i ke kū hoʻokahi ma luna o ka hopena a me ka ʻoluʻolu o ka noʻonoʻo. Pono e noʻonoʻo i ka lōʻihi loa o ka nui o ka vildagliptin i kēlā me kēia lā he 100 mg.

Kuhi ʻia ka paena mua o Galvus Met e pili ana i ka lōʻihi o ke kau ʻana o ka maʻi maʻi, ka pae o ka glycemia, ke ʻano o ka mea maʻi a me nā regimen mua hoʻohana me ka vildagliptin a me / a me metformin paha.

Hoʻomaka ka hana no ka maʻi diabetes mellitus type 2 me ka lawa ʻole o ka hoʻomaʻamaʻa ʻana a me ka papa ʻaina: 1 papa 50 + 500 mg 1 manawa i kēlā me kēia lā, ma hope o ka loiloi ʻana i ka hana pono, e piʻi ikaika ka nui o ka pāheʻe i 50 + 1000 mg 2 mau manawa i ka lā.
e mālama ai i nā hihia o ka hana pono ʻole o ka monotherapy me vildagliptin: mau manawa 2 i ka lā, 1 papa 50 + 500 mg, hiki ke hoʻonui ikaika ʻia ma hope o ka loiloi ʻana i ka hopena therapeutic,
e mālama ai i nā hihia o ka hoʻopiʻi ʻana o ka metformin monotherapy: 2 mau lā i ka lā, 1 papa 50 + 500 mg, 50 + 850 mg a 50 + 1000 mg (hilinaʻi i ka ʻano o ka metformin i lawe).
ke mālama nei i nā hihia o ka hui pū ʻana me ka metformin a me vildagliptin i ke ʻano o nā papa i hoʻokaʻawale: ka palena kokoke loa i ka ʻoniʻohana, i ka wā e hiki mai ana, i ke ʻano o kona pono, lawe ʻia kona hoʻoponopono ʻana.
hui pū me ka hoʻohana ʻana iā Galvus Met i hui pū me ka derogatives sulfonylurea a i ʻole insulin (ua wae ʻia ka makeʻe mai ka helu ʻana): vildagliptin - 50 mg 2 mau manawa i ka lā, metformin - i kahi lemike like me ka mea i hana ʻia ma mua o ka lāʻau hoʻokahi.

ʻO nā mea maʻi me ka hoʻopale ʻana ma kahi o 60-90 ml / min pono e koi aku i ka hoʻoponopono ʻana o Galvus Met. Hiki iā ia ke hoʻololi i ka hoʻoponopono o ka dosage i nā mea maʻi ma mua o 65 mau makahiki o ka makahiki, i pili ʻia me ka hopena o ka hana renal impaired (koi ʻia ka mākaʻikaʻi mau i nā hōʻike.

Nā Hoʻohui

ʻAʻole kuhikuhi ʻia ʻo Galvus Met no:

kiʻekiʻe loa hoʻohaʻahaʻa i kāna mau mea,
nā mālamalama maikaʻi ʻole a me na pilikia e ae i ka hana ana o na pu,
nā hana ʻino o nā maʻi e hiki ai i ke kumu o ka hoʻomohala ʻana i ka hana renal impaired - nāwaʻi, nā huehae, nā maʻi, nā hypoxia a pela aku
lawelawe aho ʻaia,
maʻi diabetes type 1,
aioha waiʻonanā make wai huakino
lactation, o ka hāpai ʻana,
hāpai haipulekākaʻai,
keiki malalo o 18 makahiki.

Me ka mālama aka, ua kuhikuhi ʻia nā papa i nā maʻi mai 60 mau makahiki e hana ana i ka hoʻoulu kino kino, ʻoiai hiki ke hoʻomohala ʻia lactic acidosis.

Ke keu

E like me kāu e ʻike ai vildagliptin e like me ka mahele o kēia lāʻau lapaʻau ke hoʻomanawanui maikaʻi inā mālama ʻia i loko o kēlā me kēia lā i kahi kiʻekiʻe a 200 mg. I nā hiʻohiʻona ʻē aʻe, ka hiʻohiʻona o ka ʻeha o ka ʻāʻī, ka huhū a fiva. ^ E Ha yM. ʻO ka maʻamau, hiki ke hoʻopau ʻia nā hōʻailona overdose e ka hoʻokuʻu ʻana i ka lāʻau.

I nā hihia o ka overdosemetformin, nā hōʻailona e hiki ke ulu i ka wā e lawe i ka lāʻau lapaʻau mai 50 g, ka loaʻaʻana o hypoglycemia, lactic acidosisukaia epaila, ka lua, huehu, hoʻohaʻahaʻa i ke ʻano kino o ke kino, ʻeha ma ka ʻōpū a me nā ʻōpū, wikiwiki ka ʻōpū, haki. ʻO ke ʻano koʻikoʻi e alakaʻi i ka ʻike hemahema a me ka hoʻomohala ʻana koma.

I kēia hihia, e mālama ʻia ana ka hana hōʻailona maʻi, ua hana ʻia ke kaʻina hana hemodialysis a pela aku.

Pono e hoʻomanaʻo no ka poʻe maʻi e loaʻainsulin, ʻo ke koho ʻana iā Galvus Met ʻaʻole kahi hakahaka insulin

Hoʻohui

Vildagliptin ʻaʻole kūpono cytochrome enzyme substratesP450, ʻaʻole ia he mea hoʻohui a me ka mea hoʻohālike o kēia mau enzyme, no laila, ʻaʻole hele mua ka launa me nā substrates, inducers a i ʻole P450 inhibitors. I ka manawa like, ʻo kāna hoʻohana pinepine ʻana me nā substrates o kekahi mau enzyme ʻaʻole i pili i ka helu hoʻokūkū kēia mau māhele.

Hoʻohana pū kekahi vildagliptina me nā mea ola ʻē aʻe i kauoha ʻia no kadiabetes type 2no ke ʻano: ʻO Glibenclamide, pioglitazone, metformin a me nā lāʻau lapaʻau me ka puʻupuʻu palahalaha pōkole -amlodipine, digoxin, ramipril, simvastatin, Valsartan,warfarin ʻaʻole e hoʻohālikelike i ka pili ʻana o nā maʻi.

Kahiʻa huluhula ametformin ka hopena like me ka paʻa o kēia mau mea i ke kino. Nifedipine hoʻonui i ka absorption a me ka excretion metformin i ka hoʻonohonohoʻana o ka urine.

Nā hui loinae like me: Amiloride, Digoxin, Procainamide, Quinidine, Morphine, Quinine,Ranitidine, Trimethoprim, Vancomycin, Triamteren a me nā mea ʻē aʻe i ka wā e launa pū memetformin ma muli o ka hoʻokūkū no ka halihali ākea o nā ʻāpana renal, hiki iā lākou ke hoʻonui i kona hoʻokalakupua i ka mea hoʻonohonoho pili koko. ^ E Ha yM. No laila, pono o ka hoʻohana ʻana o Galvus Met i kēlā mau hui hoʻohui.

ʻO ka hui pūʻana o ka lāʻau lapaʻau me nā thiazideskekahi diuretics, phenothiazines, Hoʻom papa ʻano maʻi thyroid estrogens, contraceptives waha,phenytoin, waikeka nicotinic,sympathomimetics, nā antagonist calcium a isoniazid, Hiki ke hoʻonāukiuki i ka hyperglycemia a hōʻemi i ka hopena o nā mea hoʻonā hypoglycemic.

No laila, i kauoha ʻia nā lāʻau like ʻole a kāpae ʻia i ka manawa like, e koi pono ka nānā ʻana o ka hana pono metformin - kona hopena hypoglycemic a, inā pono, hoʻoponopono hoʻoponopono dosage. Mai ka hui pū me danazol ua hōʻike ʻia e haʻalele i ka mea e pale aku ai i ka hōʻike ʻana o kona hopena hyperglycemic.

ʻO ka helu kiʻekiʻe Nālailaxhiki ke hoʻonui i ka glycemia, no ka mea e hoʻohaʻahaʻa i ka hoʻokuʻu i nā insulin. Hoʻomaʻamaʻa nā kinipōpō koi pū kekahi i ka hoʻoponopono ʻana i ka dosage a me ka kaohi o ka glucose.

Hoʻohui hui menā iodine-uhi i ka radiopaquehoʻāla, no ka laʻana, hana i kahi noi radiological me kā lākou hoʻohana, hana pinepine i ka hoʻomohala ʻana o ka acidact lactic acid ma ka maʻi mellitus a me nā hana renal gagal.

Hoʻokomo ʻia e hoʻonui i ka glycemia β2-sympathomimetics ma muli o kahi hōʻala ʻana i nā ʻenehana β2. No kēia kumu, pono ʻoe e hoʻokele glycemiahiki ke koho insulin

ʻĀwili hoʻokipa ʻana Metformin a huikaʻi, acarbose insulin, paʻakaihiki ke hoʻoikaika i ka hopena hypoglycemic.

ʻO ka hiʻohiʻona o ka lāʻau lapaʻau

ʻO nā mea hana o kēia lāʻau lapaʻau: vildagliptin, hiki ke hoʻokaʻawale i ka enzyme dipeptyl peptidase-4, a me ke metformin, nona nā papa o ka biguanides (nā lāʻau lapaʻau e hiki ke hoʻokaʻawale i ka gluconeogenesis). ʻO ka hui pū ʻana o kēia mau māhele ʻelua i hāʻawi ʻia ka ʻike nui aʻe o ka nui o ka glucose i ke koko. He aha ka mea ʻē aʻe o Galvus Met?

Aia ʻo Vildagliptin i ka hui o nā mea e hiki ke hoʻomaikaʻi i nā hana o nā alpha a me nā cell beta i loaʻa i ka pancreas. Hoʻomaka ʻo Metformin i ke kāpili ʻana o ka glucose i loko o ke akea a hoʻēmi i kona kao ʻana i loko o ka pānaʻi.

ʻO ke kumu kūʻai o Galvus Met he mea hoihoi i ka nui.

Ka hoʻoponopono palapala ʻana a me nā ʻōlelo kauoha no ka hoʻohana ʻana i ka lāʻau lapaʻau

No ka hōʻemi i nā hopena ʻino, e kuhi ʻia e inu ia i ka wā o ka papaʻaina. ʻO ka mau kauā e hōʻike ʻia ʻana he hoʻokahi haneli mg / lā.

Koho ʻia ka hewa o Galvus Met e ke kauka komo e kū hoʻokahi, e pili ana i ka hopena o nā mea a me kā lākou kāhea i ka mea maʻi.

I ka hoʻomaka mua o ka lāʻau lapaʻau, i ka haʻalele ʻana o ka vildagliptin, ua kau ʻia ke kaha, hoʻomaka ʻia me hoʻokahi papa o ka lāʻau 50/500 mg papalua i hoʻokahi lā. Inā loaʻa kahi hopena kūpono i ka lāʻau, a laila hoʻomaka ka make i ka hoʻonui.

I ka hoʻomaka mua o ka lāʻau lapaʻau me ka lāʻau lapaʻau ʻo Galvus Met, me ka ʻole o ka metformin ke ʻano, i ke ʻano o ka ʻomo ʻana i lawe ʻia, kauoha ʻia ke ʻano hoʻomaka me kahi 50/500 mg, 50/850 mg a i ʻole 50/1000 mg lāʻau lapaʻau ʻelua ʻelua a lā.

I ka manawa mua o ka lāʻau lapaʻau ʻo Galvus Met, nā mea maʻi i mālama mua ʻia me ka metformin a me vildagliptin, ma muli o ka hāmeʻa a kā lākou i lawe ai, e kau ʻia i kahi maʻi ma kahi kokoke e like me nā mea e pili ana i ka 50/500 mg, 50/850 mg a 50/1000 mg ʻelua i ka la hou i.

ʻO ka hopena mua o ka lāʻau “Galvus Met” no nā poʻe me ka lua o ka maʻi mellitus no ka maʻi o ka hana ʻana o nā hana physiotherapy a me kaʻai ʻana ma ke ʻano he maʻi kumu mua loa ʻo 50/500 mg i hoʻokahi lā. Inā loaʻa kahi hopena kūpono i ka lāʻau, a laila hoʻomaka ka make i ke 50/100 mg papalua i ka lā.

E like me ka hōʻike ʻana a ke kumu aʻo Galvus Met, no ka hui pū ʻana me ka insulin, ʻo ka nui i ʻōlelo ʻia e 50 mg ʻelua i kēlā me kēia lā.

ʻAʻole pono e hoʻohana ʻia ka lāʻau lapaʻau e nā mea me ka renal dysfunction a i ʻole ka hopena ʻole.

No ka mea ua hoʻopau ʻia ka lāʻau lapaʻau e nā pēpē, no nā poʻe maʻi nā ʻoi aku ma mua o 65 mau makahiki o ka makahiki i loaʻa ke ʻano o ka hana hana, ua ʻōlelo ʻia ʻo Galvus Met e lawe ʻia me ka liʻiliʻi liʻiliʻi, ʻo ia ka mea e hōʻoia ai i ka normalization o ka glucose. Pono ke nānā pono ʻana i nā hana i ʻole.

Ua hoʻohana ʻia ka hoʻohana ʻana no nā keiki, no ka mea, ʻaʻole i aʻo pono ka maikaʻi a me ka palekana o ka lāʻau no nā keiki.

I ka wahine hāpai a me nā lactating

Hoʻopili ʻia ke hoʻohana ʻana o Galvus Met 50/1000 mg i ka wā hapai, no ka mea, ʻaʻole i lawa nā ʻike ma ka hoʻohana ʻana i kēia lāʻau lapaʻau i kēia manawa.

Inā pilikia ka glucose metabolism i ke kino, a laila hiki i ka wahine hāpai ke piʻi ka nui o ka hoʻomohala ʻana i nā anomalies congenital, make, a me ka pinepine o nā maʻi neonatal. I kēia hihia, pono e lawe ʻia ka monotherapy me ka insulin e hoʻomaʻamaʻa i ka glucose.

Ua hoʻohana ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau i nā makuahine hānai, no ka mea ʻaʻole i ʻike ʻia inā ua hoʻopili ʻia nā mea o ka lāʻau (vildagliptin a me ka metformin) i loko o ka waiū umauma o ke kanaka.

Nā ʻōlelo kikoʻī

Ma muli o ke koina o ka vildagliptin i hoʻonui ʻia ka hana o aminotransferase, ma mua o ka kuhikuhi ʻana a ma ka wā i mālama ʻia me ka lāʻau maʻi maʻi maʻi ʻo "Galvus Met", pono e hoʻoholo pinepine ʻia nā ʻōkuhi hana.

Me ka hōʻuluʻulu ʻana o ka metformin i loko o ke kino, hiki ke kūpono i ka acidact lactic, kahi ʻano nui loa ia, akā loaʻa i kahi maʻi koʻikoʻi metabolic koʻikoʻi. Kūkulu, me ka hoʻohana ʻana o ka metformin, ua nānā ʻia ka lactic acidosis i nā mea maʻi me ka maʻi maʻi i loaʻa i kahi pae koʻikoʻi o ka pilikia ʻole. Eia nō hoʻi, ʻo ka hōʻeha o ka acidact lactic hoʻonui i loko o kēlā mau maʻi me ka maʻi maʻi i make pōloli no ka manawa lōʻihi, he paʻakikī no ka mālama ʻana, ua hoʻolōʻihi wau i ka waiʻona a i ʻole ka maʻi ʻeha.

Nā hiʻohiʻona o ka lāʻau

ʻO nā analogues o "Galvus Meta" i loko o kahi hui lāʻau lapaʻau e komo:

"Avandamet" - kahi hui hoʻohui hypoglycemic hui i loaʻa i ʻelua māhele nui - metformin a me rosiglitazone. Ua kuhikuhi ʻia ka lāʻau lapaʻau no ka mālama ʻana i kahi ʻano hana i hana ʻia i ka inanene. Hoʻolālā ʻo Metformin i ka pale ʻana i ke kāpili ʻana o ka glucose i loko o ke akea, a me ka rosiglitazone - e hoʻonui ana i ka ʻike ʻana o nā cell cellers i ka insulin. ʻO ke kumukūʻai kūpono o kahi lāʻau lapaʻau he 210 mau ruble no kēlā me kēia papa o 56 papa i kahi kaona o 500/2 mg. Pono ke koho ʻana i nā nogona "Galvus Met" e ke kauka.
"Glimecomb" - hiki nō iā ia ke hana maʻamau i ke kūlohelohe o ka glucose. Ke loaʻa nei ka lāʻau lapaʻau me ka metformin a me gliclazide. Hoʻokomo ʻia kēia lāʻau lapaʻau i nā maʻi maʻi kanaleka a me ka poʻe maʻi, nā kānaka i loko o kahi mākaʻi, nā wahine hāpai, e hōʻeha ana i ka hypoglycemia a me nā ala āpau. ʻO ka kumukūʻai kūpono o ka lāʻau lapaʻau he 450 mau rubles no ka pā o 60 papa.
"Combogliz Prolong" - loaʻa i ka metformin a me saxagliptin. Ua kuhikuhi ʻia ka lāʻau lapaʻau no ka mālama ʻana i ke ʻano o ka maʻi mellitus o ke ʻano ʻelua, ma hope o ka nele o ka hana pono o nā hoʻomaʻamaʻa kino a me ka ʻai. Hoʻomaʻamaʻa ʻia kēia lāʻau lapaʻau no nā poʻe me ka hypersensitivity i nā mea nui i hana i ka lāʻau lapaʻau, kahi ʻano like ʻole o ka maʻi maʻi o ka insulin, ka hānau ʻana i kahi keiki, nā keiki liʻiliʻi, ʻo ka ʻōpū a me nā hana hoʻi o ka ate. ʻO ka kumukūʻai kiʻekiʻe o ka lāʻau lapaʻau he 2,900 rubles no kēlā me kēia papa o 28 mau papa.

"ʻO Januvia" kahi kikowaena hypoglycemene, aia i ka sitagliptin hāmeʻa neʻe. Ke hoʻohana nei i ka lāʻau lapaʻau i ka pae o ka glycemia a me ka glucagon. Hoʻoholo ʻia ka dosage e ke kauka hele mai, i mea e manaʻo ai i ka pauʻa o ke kō, ke olakino ākea a me nā mea ʻē aʻe. Ua hoʻohālikelike ʻia ka lāʻau i ka poʻe me ka diabetes-depend-dependence a me nā intolerance pilikino i nā ʻāpana. I ka wā o ka mālama ʻana, ka ʻeha, ka indigestion, nā ʻeha hui, a me nā maʻi ʻeha o ka ʻōpū. I ka awelika, ʻo ka uku kumukūʻai o ka laʻana he 1600 rubles.
"Trazhenta" - hiki i ka hui ke loaʻa i ka hana o nā papa me ka linagliptin. E hoʻonāwaliwali ia i ka gluconeogenesis a hoʻopaʻa i nā pae o ke kō. Koho ke kauka i nā dosages pakahi no kēlā me kēia maʻi.
He nui nā mea hana like o Galvus Met.
Kūʻai nā kumukūʻai no galvus i nā lāʻau lapaʻau ma Moscow

pani ʻ -lelo ʻlelo 50 mg + 1000 mg 30 kiʻi ≈ 1570 rub.

50 mg + 500 mg 30 kiʻi ≈ 1590 rub.

50 mg + 850 mg 30 kiʻi ≈ 1585.5 ʻōpala.

Hōʻike nā kauka e pili ana i nā kauka e pili ana i ka galvus meta

Ka Helu 3.8 / 5

Ioaaaia

Kūʻai / maikaʻi

Nā hopena hopena
ʻO Galvus Met kahi lāʻau lapaʻau maʻamau maʻamau no ka mālama ʻana i ka maʻi maʻi 2. He kūpono a palekana ia i ka haʻalele ʻana o contraindications. ʻO ka haʻahaʻa glucose me ka ʻole o ka hopena o ka hypoglycemia. Ke hoʻohana nei ka lāʻau lapaʻau i kahi hoʻomau mau, mau nui i ka nui o ka glucose i loko o ke ao. Eia kekahi, ua emi iki ka emi o ke kahe koko i nā maʻi i hōʻeha ʻia i ka hypertension. ʻAʻole ia e hāʻawi i ka lilo nui o ka mea maʻi. He kumukūʻai kūpono maʻalahi no ka poʻe maʻi.

Rating Rating / 5

Ioaaaia

Kūʻai / maikaʻi

Nā hopena hopena
ʻO kahi hui maikaʻi e hoʻomaka i ka mālama ʻana i ka maʻi maʻamau ʻo 2. Hāʻawi ka hui pū i ka maʻalahi a me ka maʻalahi o ka hoʻokele ʻana, me ka ʻoi aku ka maikaʻi a me ka hiki ke hoʻohālikelike ʻia me monotherapy, ka hiki ke hana ma nā wahi pathological nui i ka manawa like. ʻAʻohe ona hopena, hopena hopena ʻole, aneane ʻaʻole contraindications.

Rating Rating / 5

Ioaaaia

Kūʻai / maikaʻi

Nā hopena hopena
ʻO ka heleʻana o nā palapala me nā ʻāpana like o ka metformin.
ʻO ka hui pūʻana o ʻelua mau lāʻau maikaʻi no ka mālama ʻana i ka maʻi diabetes 2 ʻano. ʻAʻole hiki i ka lāʻau lapaʻau ke alakaʻi i ka hypoglycemia, a no laila ke aloha ʻia e nā kauka, ma oʻu wale nō, a me nā mea maʻi. Hiki ke hoʻohana ʻia ʻaʻole e pili me ka hoʻopale ʻana o ka meaʻai me ka hoʻomanawanui maikaʻi, a i ʻole a i ʻole ma hope o ka ʻai me nā hopena maikaʻi ʻole.
Hōʻikeʻike i nā maʻi e pili ana i ka galvus meta
Ua loaʻa iaʻu kahi maʻi diabetes mai ka makahiki 2005, no ka manawa lōʻihi, ʻaʻole hiki i nā kauka ke loaʻa i nā lāʻau kūpono. ʻO Galvus Met koʻu ola. Ua mālama wau iā 8 mau makahiki a ʻaʻole wau i loaʻa i kahi mea maikaʻi aʻe. ʻAʻole wau makemake makemake e hoʻololi i nā injections o ka insulin, ʻo ia ʻo Galvus Met e mālama mau ana i ke kō i ka maʻamau. Aia ma kahi papa he 28 i loko o kahi pā - Ua lawa wau no 2 wiki, inu wau i ke kakahiaka a me ke ahiahi. ʻAʻole au e lawe i nā lāʻau lapaʻau ʻē aʻe.
E kūʻai mau ana wau i kēia lāʻau lapaʻau no koʻu māmā. Ua maʻiʻo ia i ka maʻi maʻi ma mua o hoʻokahi haneli. Ua kūpono iā ia. Me ka hoʻohana maʻamau o kēia lāʻau lapaʻau, makemake nui ʻo ia. Aia nō ia e poina iā ia e kūʻai i kahi pā, a pau ka mea kahiko, a laila weliweli wale kona kūlana. Ke piʻi nei ke kō koko, ʻaʻole hiki iā ia ke hana i kekahi mea, ke hoʻopunipuni wale nō a lawe aku ʻo ia i kēia paila. Ke kūʻai aku nei au i nā lāʻau lapaʻau no nā mākua, no laila ʻike wau e ʻae ʻia ke kumukūʻai o kēia lāʻau lapaʻau, a hui nui kēia.
ʻO ka wehewehe pōkole
ʻO Galvus Met kahi hui pū i hui pālua (vildagliptin + metformin) lāʻau lapaʻau no ka mālamaʻana i ka non-insulin-hilinaʻi (2 mau ʻano) maʻi mellitus. Hoʻohana ʻia inā ʻaʻole e lawa ka maikaʻi o ka mālama ʻana i kēlā me kēia lāʻau, a i nā mea maʻi i hoʻohana mua ʻia ʻo vildagliptin a me ka metformin i ka manawa like, akā ma ke ʻano o nā lāʻau hoʻokaʻawale. ʻO ka hui pūʻana o vildagliptin + metformin e hiki ke hoʻokele maikaʻi i ka pae o ka glucose i ka lā. Hana ʻo Vildagliptin i nā ʻāpana poli pancreatic i ʻoi aku ka naʻau i ka glucose, a ma ka ʻaoʻao o ka hapa huna o ka glucose e hilinaʻi i loko. I nā poʻe olakino (ʻaʻole e luhi i ka maʻi mellitus), ʻaʻohe hopena o vildagliptin i kēlā hopena. Hāʻawi ʻo Vildagliptin i ka mana kūpono ma luna o ka hoʻoponopono ʻana i ka mea huna o ka ʻāuna anagonine, ka hormone o nā pūpū o nā ʻāpana o nā mokupuni o Langerhans glucagon, a, ke hoʻohālikelike nei i ka pane o ka metabola o nā kiko i ka endogenous a i ka exogenous insulin. Ma lalo o ka hana a vildagliptin, ua kau ʻia ka gluconeogenesis i loko o ka pepi, ma muli o ka hōʻemi ʻia o ka glucose glucose i mālama ʻia. Ke kōkua nei ka Metformin e hoʻohaʻahaʻa i nā haʻahaʻa ka wai koko me ka manaʻo ʻole o ka meaʻai (i.e., ma mua o a ma hope o ka ʻai), e hoʻomaikaʻi ai i ke kāhea ʻia o ka glucose i nā poʻe me ka diabetes mellitus-non-insulin. Hoʻopili ka Metformin i ka glucoseoneogenesis i loko o ka puʻuwai, e hoʻopili ai i ka lilo ʻana o ka glucose i loko o ka kūnaehana ʻana, hoʻomaikaʻi i ka pane ʻana o ka metabolic o nā kiko i ka insulin.
ʻAʻole i like me derivatives sulfanilurea (glibenclamide, glycidone, glyclazide, glimepiride, glipizide), metformin ʻaʻole ia e waiho i ka emi o ka glucose i lalo o ka maʻamau o ka physiological ma o ka maʻi maʻi a me nā mea olakino paha. ʻAʻole he kumu o ka Metformin i ka piʻi o ka pathological i nā pae insulin i ke koko a ʻaʻole i hoʻopilikia i kāna nalo. He hopena maikaʻi ka Metformin ma ka ʻōlelo lipid: hoʻemi i ka pae o ka nui, a pēlā aku. "Kino" kino, triglycerides. ʻO ka hui pūʻana o ka vildagliptin + metformin ʻaʻole e loli i ka nui o ke kaumaha o ke kino. Koho ʻia ka nui o ka lāʻau i kēlā me kēia kanaka ma muli o ka pane a me ke hoʻomanawanui. Noi ʻia ke ʻano o ka pauku mua e noʻonoʻo i ka ʻike o ka mea maʻi me ka lāʻau lapaʻau me ka vildagliptin a me ka metformin. ʻO ka manawa kūpono loa no ka lawe ʻana iā Galvus Met me ka meaʻai (ʻo ia ka mea hiki iā ʻoe ke hoʻokaʻawale i nā ʻaoʻao ʻaoʻao o ka metformin ma ka gastrointestinal tract). ʻAʻole hiki iā Galvus Met ke hoʻololi i ka insulin exogenous i nā maʻi e lawe nei i ka hoʻomākaukau ʻana i ka insulin. ʻOiai e lawe ana i ka lāʻau lapaʻau, pono ia e nānā i nā lāʻau lapaʻau a me nā hana o ka hana o ka puʻuwai, me ka loiloi o ka hana renal. Inā pono e hoʻokō i nā ʻanā pale ʻana, e hoʻopau ʻia ka lāʻau me Galvus Met. Ethanol potentiates ka hopena o ka metformin ma ka metabolism o ka lactate, no laila, i pale aku ai i ka hoʻomohala ʻana o ka lactic acidosis mai ka waiʻona i ka wā e hoʻohana ai iā Galvus Met, pono pono e hōʻole.
Lapaʻau
ʻO ka lālani hypoglycemic waha i hoʻohui ʻia. ʻO ka pūnaehana o ka lāʻau Galvus Met ka mea komo ʻelua mau pūmole hypoglycemic me nā ʻano hana like ʻole: vildagliptin, no ka papa o ka dipeptidyl peptidase-4 inhibitors (DPP-4), a me metformin (ma ke ʻano o ka hydrochloride), he mākaukau o ka papa biguanide. ʻO ka hoʻohui ʻana o kēia mau mea e hiki ai iā ʻoe ke hoʻomaikaʻi maikaʻi i ka piʻi ʻana o ka glucose i ke koko i loko o nā mea maʻi me ka maʻi type 2 i loko o 24 mau hola.
ʻO Vildagliptin, he māka o ka papa o ka mea hoʻolaha o ka insular pancreatic apparatus, sellyly pale i ka enzyme DPP-4, ka mea e hoʻopau i ka type 1 glucagon like-peptide (GLP-1) a me ka glucose-dependantine insulin -ropyp polypeptide (HIP).
Hoʻopau ka wikiwiki a me ka hoʻopau ʻana i ka hana DPP-4 e hoʻonui i ka pālua a me ka hoʻowaleu ʻia ʻana o ka ʻai me GLP-1 a me HIP mai ka ʻōpū i loko o ka ʻōnaehana ʻōnaehana i ka lā a pau.
Ke hoʻonui nei i ka kao o GLP-1 a me HIP, ʻo vildagliptin e hoʻonui i ka naʻau o ka pancreatic β-cells i ka glucose, e alakaʻi ai i kahi hoʻomaikaʻi ʻana i ka huna o ka glucose i hilinaʻi ʻia. Hōʻike ka nui o ka holomua o ka hana o ka β-cell i ka pae o ko lākou hōʻeha mua, no laila i loko o nā poʻe me ka maʻi mellitus ʻole o ka diabetes mellitus (me ka plasma glucose kumu maʻamau), ʻaʻole i hoʻonā ka vildagliptin i ka huna ʻana i ka insulin a ʻaʻole e hōʻemi i ka kukuna glucose.
I ka hoʻonui ʻana i ka kao o ka endogenous GLP-1, hoʻonui ka vildagliptin i ka hoʻololi ʻana o nā seleka o ka glucose i ka glucose, e alakaʻi ai i kahi holomua o ka hoʻoponopono o ka glucose i kālai ʻia ʻana o ka paleona. ʻO ka emi ʻana o ka hoʻāla ʻia o ka glucoseagon i ka wā o ka pāʻina, ma ka huli ʻana, e hoʻohemo ai i ka pale ʻana i ka insulin.
ʻO ka hoʻonui ʻana o ka pāʻana o ka insulin / glucagon e kū'ē ana i ke kua o ka hyperglycemia, ma muli o ka hoʻonui ʻana o ka neʻe o ka GLP-1 a me HIP, e hoʻolilo i ka emi ʻana o ka hana o ka glucose i ka ate ma ka wā a ma hope o ka ʻaina, ka mea e alakaʻi ai i ka emi o ke kaʻe o ka glucose i loko o ke kaila koko.
Eia kekahi, e kū'ē i ka hope o ka hoʻohana ʻana o vildagliptin, kahi i hoʻohaʻahaʻa i ka hoʻoweliweli o lipids i ka plasma koko ma hope o ka māka ʻana o ka pāʻina, akā naʻe, ʻaʻole pili kēia hopena i kona hopena i ka GLP-1 a i ka HIP a me kahi hoʻomaikaʻi ʻana i ka hana o nā kuleana pālima pancreatic.
Ua ʻike ʻia ka piʻi ʻana o ka neʻe o ka GLP-1 hiki ke alakaʻi i ka ʻohi ʻana i ka ʻōpū o ka ʻōpū, akā naʻe, i ke ʻano o ka hoʻohana ʻana o vildagliptin, ʻaʻole i mālama ʻia kēia hopena.
Ke hoʻohana nei i vildagliptin i 5759 nā mea maʻi me ka diabetes mellitus type 2 no 52 mau wikiʻa e like me ka monotherapy a i hui pū ʻia me metformin, derivl o ka sulfonylurea, thiazolidinedione, a i ʻole insulin, he nui ka manawa lōʻihi o ka hōʻemi o ka neʻe o ka hemoglobin glycated (HbA_1s) a me ka hookeai koko i ke koko.
Hoʻoulu ka Metformin i ka hoʻohaʻahaʻa glucose i nā maʻi me ka maʻi type 2 ma ka hoʻohaʻahaʻa ʻana i nā kukuna glucose glucose ma mua a ma hope o ka ʻai. Hoʻemi ka Metformin i ka hana o ka glucose i ka peka, e hōʻemi ana i ka lilo ʻana o ka glucose i loko o ka pūpoki a me ka hoʻohaʻahaʻa ʻana i ka kūleʻa o ka insulin ma o ka hoʻomaikaʻi ʻana i ka hoʻoulu ʻana a me ka hoʻohana ʻana i nā kūmole i nā kikoʻī peripheral. ʻAʻole i like me derivatives sulfonylurea, ʻaʻole ka metformin i ka hypoglycemia i nā mea maʻi me ka diabetes mellitus type 2 a i nā poʻe olakino (koe wale nō nā hihia kūikawā). ʻAʻole ke alakaʻi i ka lāʻau lapaʻau me ka hoʻomohala ʻana o ka hyperinsulinemia. Me ka hoʻohana ʻana o ka metformin, ʻaʻole i loli ka huna ʻana o ka insulin, ʻoiai e emi ana ka manaʻo o ka insulin i ka plasma ma kahi ʻōpū ʻole a i ka lā e emi ana ka lā.
Hoʻokomo ka Metformin i ka syntact glycogen intracellular ma o ka hana ʻana ma ka synthase glycogen a hoʻonui i ka halihali glucose e kekahi mau protein transporter glucose membrane (GLUT-1 a me GLUT-4).
Ke hoʻohana nei i ka metformin, he hopena maikaʻi i ka metabolism o nā lipoproteins i hōʻike ʻia: kahi emi o ka neʻe o ka kolamu nui, LDL cholesterol a me TG, ʻaʻole pili me ka hopena o ka lāʻau lapaʻau i ka hoʻoliʻi glucose glucose.
Ke hoʻohana nei i ka hopena hui me vildagliptin a me ka metformin i nā lā i kēlā me kēia lā he 1500-3000 mg o ka metformin a me 50 mg o vildagliptin 2 mau manawa / lā no 1 makahiki, he kupanaha kaila nui a ka kaila i ka pau ʻana o ka glucose koko i nānā ʻia (i hoʻoholo ʻia e ka hoʻemi ʻana o HbA_1s) a me ka hoʻonui ʻana o ka hapa i nā mea maʻi me ka hoʻēmi ma HbA_1s mau kālā ma ka liʻiliʻi he 0.6-0.7% (hoʻohālikelike ʻia me ka pūʻulu o nā maʻi i hoʻomau i loaʻa i ka metformin wale nō).
I ka poʻe maʻi e loaʻa ana i ka hui pū ʻana me vildagliptin a me ka metformin, he loli nui i ka nui o ke koʻikoʻi o ke kino i hoʻohālikelike ʻia me nā kūlana mua.24 mau pule ma hope o ka hoʻomaka ʻana o ka hoʻōla, ma nā pūʻulu o nā mea maʻi e loaʻa ana i ka vildagliptin i hui pū me ka metformin, i ka emi ʻana o ko systolic a me ka diastolic i ke koko i nā mea maʻi me ka hypertension arterial.
I ka manawa o ka hui pū ʻana o ka vildagliptin a me ka metformin i hoʻohana ʻia ma ke ʻano he mālama mua no nā poʻe maʻi me ka maʻi diabetes mellitus type 2, ua mālama ʻia kahi ʻano hoʻēmi o HbA no 24 mau pule_1s kaupaona kino me ke hoʻohālikelike ʻana me ka monotherapy me kēia mau lāʻau. ʻO nā hihia o ka hypoglycemia ka liʻiliʻi ma ka hui mālama ʻelua.
Ke hoʻohana nei i vildagliptin (50 mg 2 mau manawa / lā) a i ʻole / me ke ʻano o metformin e hui pū me ka insulin (ma o awelika o 41 PIECES) i nā mea maʻi i ka noiʻi kulekele, ʻo ka māka HbA_1s a emi iki i ka helu statistically - e 0.72% (kuhikuhi mua - he awelika o 8,8%). ʻO ka ulu ʻana o ka hypoglycemia i ka hui mālama ʻia i hoʻohālikelike ʻia me ka hoʻoulu ʻana o ka hypoglycemia i ka hui plasebo.
Ke hoʻohana nei i vildagliptin (50 mg 2 mau manawa / lā) e hui pū ai me metformin (≥1500 mg) e hui pū ai me glimepiride (≥4 mg / lā) i nā mea maʻi i ka noiʻi lāʻau lapaʻau, ʻo ka māka HbA_1s ka hoʻohaʻahaʻa ʻana i ka helu - ma ka 0.76% (mai ka pae awelika - 8.8%).
Lapaʻau lāʻau
Ke lawe ʻia ma luna o kahi ʻōpū, ua lawe koke ʻia ke vildagliptin, a me kāna C_max ua loaʻa 1.75 mau hola ma hope o ka hoʻokele ʻana. Me ka hiki ʻana i ka mea ʻai me ka meaʻai, e emi iki ana ka nui o ka ʻike ʻana o ka vildagliptin: kahi hōʻemi o C_max e 19% a me ka hoʻonui ʻana o ka manawa e hōʻea i nā hola 2.5. Akā, ʻaʻole e pili ka ʻai i ke kiʻekiʻe o ka pā a me ka AUC.
Hoʻopili koke ʻia ʻo Vildagliptin, ʻo ka bioavailability kūʻokoʻa ma hope o ke alakaʻi waha ʻana he 85%. C_max a me AUC o ka nui o ka maʻi therapeutic e hoʻonui i ke kokoke i ke kaawale o ka nui.
ʻO ka palena o ka vildagliptin i nā protein plasma he haʻahaʻa (9.3%). Kālaha ʻia ka lāʻau lapaʻau ma waena o ka plasma a me nā wahi hoʻoliʻiliʻi koko. Hoʻopili ʻia ka hoʻoili ʻana ʻo Vildagliptin, V_{ai ʻo ss} ma hope o ka lawelawe ʻana iv he 71 lita.
ʻO Biotransformation ke ala nui o ka excretion o vildagliptin. I ke kino o ke kanaka, ua hoʻohuli ʻia ka 70% o ka nui o ka lāʻau. ʻO ka metabolite koʻikoʻi - LAY151 (57% o ka momona) he pharmacologically aktive a he mea ia o ka hydrolysis o ka māhele cyano. Ma kahi o 4% o ka loaʻaʻana o ka lāpō e lawe i ka hydrolysis amide.
Ma nā hoʻokolohua hoʻokolohua, ʻike ʻia kahi hopena maikaʻi o DPP-4 ma ka hydrolysis o ka lāʻau. ʻAʻole emailili ʻia ʻo Vildagliptin me ka komo ʻana o nā isoenzymes cytochrome P450. Wahi a nā haʻawina vitro, ʻaʻole vildagliptin ia he lepo, ʻaʻole ia e kālai a ʻae ʻole e hoʻonāukiuki i ka isoenzymes CYP450.
Ma hope o ka helu ʻana i ka lāʻau, ua pili ka 85% o ka nui ma ka ʻōpū a me 15% ma o ka ʻōpū, ʻo ka renal excretion o vildagliptin i loli ʻole he 23%. Me ka ma / i ka hoʻomaka ʻana o ka mahele T_1/2 a hiki i 2 mau hola, ʻo ka huina piha piha plasma a me nā hoʻomaʻemaʻe o ka vildagliptin he 41 l / h a me 13 l / h. T_1/2 ma hope o ka helu ʻana ma kahi o 3 mau hola, inā paha i kauā.
ʻO ka pharmacokinetics i nā hihia lapaʻau kūikawā
ʻAʻole pili ʻo ke kāne male, ka BMI, a me ka lāhui i ka pharmacokinetics o vildagliptin.
I ka poʻe maʻi me ka hōʻemi i ka maʻi hepatic i hōʻemi (6-10 mau wahi e like me ka helu ʻana o nā keiki-Pugh), ma hope o ka hoʻohana ʻana i ka lāʻau, aia ka emi ʻana o ka bioavailability o vildagliptin e 8% a 20%, kēlā me kēia. I ka poʻe maʻi me ka maʻi hepatic koʻikoʻi (12 mau poʻo e like me ka helu ʻana o nā keiki-Pugh), hoʻonui ʻia ka bioavailability o vildagliptin e 22%. ʻO ka loli loa ma ka bioavailability o vildagliptin, he piʻi a hōʻemi paha i ka awelika a hiki i 30%, ʻaʻole ia he maʻi koʻikoʻi. ʻAʻole i hoʻoponopono ʻia ma waena o ka nui o ka hana a ke ake a me ka bioavailability o ka lāʻau.
I nā mea maʻi me ka hana renal impaired, hōʻoluʻolu, maʻalahi, a i ʻole ka nui AUC, ua hoʻonui ʻia ka vildagliptin 1,4, 1.7, a me 2 mau manawa i hoʻohālikelike ʻia me nā mea hana olakino, kēlā me kēia. ʻO ka AUC o ka metabolite LAY151 i hoʻonui i ka 1,6, 3.2 a me 7.3 mau manawa, a me ka metabolite BQS867 i hoʻonui i ka 1,4, 2.7 a me 7.3 mau manawa i nā maʻi me nā hana renal impaired o ke akene, hoʻohaʻahaʻa a me nā koʻikoʻi. Pau nā ʻikepili i nā mea maʻi me nā maʻi mākaʻomaʻo hope loa (CKD) e hōʻike ai i nā hōʻailona ma kēia pūʻulu e like pū me nā mea i nā mea maʻi me nā maʻi koʻikoʻi. ʻO ka hoʻoneʻe ʻana o Lā151 metabolite i loko o nā mea maʻi me ka hopena o ka hope CKD i hoʻonui ʻia e nā manawa 2-3 e hoʻohālikelike ʻia i ka neʻe ʻana o nā mea maʻi me nā maʻi hakahaka. ʻO ka wehe ʻana o vildagliptin i ka wā hemodialysis ua palena (3% i loko o ke kaʻina hana e ʻoi aku ma mua o 3-4 mau hola 4 mau hola ma hope o hoʻokahi pākahi.
ʻO ka hoʻonui nui loa i ka bioavailability o ka lāʻau lapaʻau ma 32% (hoʻonui i C_max 18%) i nā mea maʻi ma mua o 70 he koʻikoʻi koʻikoʻi a ʻaʻole i pili i ka pāpā ʻana o DPP-4.
ʻAʻole i hoʻokū ʻia nā hiʻohiʻona ʻo ka pharmacokinetic o vildagliptin i loko o nā keiki a me nā ʻōpio ma lalo o 18 makahiki o kona mau makahiki.
ʻO ka bioavailability kūʻokoʻa o ka metformin i ka wā i lawe ʻia ma ka lima o 500 mg ma kahi ʻōpū ʻole he 50-60%. C_max hoʻokō ma hope o 1.81-2.69 mau hola ma hope o ka hoʻokele ʻana. Me ka piʻi nui o ka lāʻau lapaʻau mai 500 mg i 1500 mg, a i ʻole e lawe ʻia i ka waha ma 850 mg a 2250 mg, he lohi ka nui o nā hiʻohiʻona pharmacokinetic i ʻike ʻia (ma mua o ka mea e manaʻo ʻia no ka pilina laina). ʻAʻole ʻia kēia hopena e ka nui o ka hoʻololi ʻana o ka hōʻemi ʻana i ka lā lapaʻau e like me ke neʻe ʻana o kona komo ʻana. E kū'ē i ka papa o ke komo ʻana i ka meaʻai, ka palena a me ka helu o ka hoʻopiʻi ʻana o ka metformin i emi iki hoʻi. No laila, me hoʻokahi mau kaha o ka lāʻau i ka maʻa o kahi o 850 mg, ua emi ka nui o C me ka meaʻai_max a AUC ma kahi o 40% a 25%, a me ka nui o ka T_max no 35 mau minuke ʻAʻole paʻa i ka maʻi koʻikoʻi o kēia mau ʻike.
Me kahi kakio waha hoʻokahi o 850 mg - ʻike ʻia V_{e d} metformin he 654 ± 358 lita. ʻAʻole pono ka lāʻau lapaʻau e nakinaki i nā protein plasma, aʻo ka pilina o ka sulfonylurea e hoʻopaʻa ʻia iā lākou ma mua o ka 90%. Hoʻomoʻa ka Metformin i nā ʻāpana koko ʻokoʻa (ʻoi paha ka ikaika o kēia kaʻina ma mua o ka manawa). Ke hoʻohana ʻia i ka metformin e like me ke ʻano maʻamau (maʻamau ka palena a me ka neʻe o ka hoʻokele) C_{ai ʻo ss} hōʻea ka lāʻau lapaʻau i loko o ke koko koko i loko o nā hola 24-48 a, ma ke ʻano he kānāwai, ʻaʻole iʻoi aku i ka 1 μg / ml. I nā hoʻokolohua hoʻokolohua hoʻokipa o C_max ʻAʻole iʻoi aku ka metformin plasma ma mua o 5 mcg / ml (inā i lawe ʻia i ka nui kiʻekiʻe).
Metabolism a me ka hoʻopā ʻana
Me kahi hoʻokele intravenous hoʻokahi i nā limahana olakino, hoʻopili ʻia ka metformin e nā loli. ʻAʻole ia i hoʻokaʻawale ʻia i ka puʻu (ʻaʻole i ʻike ʻia nā metabolites i nā kānaka) a ʻaʻole i hoʻopā ʻia i ka bile.
No ka mea ʻo ka wehe ʻana o ka renformin o ka metformin e pili ana i ka manawa o 3 mau manawa ma mua o QC, ke ala nui o ka excretion o ka lālani. I ka wā e ʻike ʻia ana, ma kahi o 90% o ka nui i ka pau ʻia i hoʻopio ʻia e nā keiki ma ka 24 mau hola mua, me T_1/2 mai ka pili koko mai e pili ana i 6.2 mau hola_1/2 metformin holoʻokoʻa holoʻokoʻa ma kahi o 17.6 mau hola, e hōʻike ana i ka hōʻemi o kahi mahele nui o ka lāʻau ma nā ʻāpana koko ʻulaʻula.
ʻO ka pharmacokinetics i nā hihia lapaʻau kūikawā
ʻAʻole pili ka kāne o nā mea maʻi i ka pharmacokinetics o metformin.
I ka poʻe maʻi me ka maʻi hepatic, ʻaʻole i hoʻopaʻa ʻia kahi noiʻi o nā ʻano lāʻau pharmacokinetic o ka metformin.
I ka poʻe maʻi me ka hana renal impaired (a nānā ʻia e QC) T_1/2 ka metformin mai plasma a me ke koko a pau, a me nā hoʻomaʻemaʻe kino āpau e hoʻemi i ka hapa i ka emi ʻana o CC.
Wahi a nā haʻawina ʻo pharmacokinetic i nā poʻe olakino i hiki i ka makahiki 65, 65, ke kaila o ka huina piha o ka plasma metformin a me ka hoʻonui ʻana o T_1/2 a C_max ua hoʻohālikelike ʻia i nā maka ʻōpio. ʻO kēia mau pharmacokinetics o metformin i kēlā me kēia kanaka ma luna o 65 mau makahiki o nā makahiki e pili pinepine nei i nā loli i ka hana renal. No laila, i nā mea maʻi i ʻoi aku ma mua o 80 mau makahiki, hiki ke koho ʻia i ka lāʻau Galvus Met hiki wale nō me nā CC maʻamau.
ʻAʻole paʻa i nā hiʻohiʻona pharmacokinetic o metformin i loko o nā keiki a me nā'ōpio ma lalo o 18 makahiki o kona mau makahiki.
ʻAʻohe mea hōʻike i ka hopena o ka hopena o ka hoʻomanawanui ma ka hiʻohiʻona pharmacokinetic o ka metformin. I nā haʻawina hoʻokolohua paʻa i ka metformin i nā maʻi me ka maʻi diabetes mellitus type 2 o nā ʻano ʻē aʻe, ua hōʻike ʻia ka hopena hypoglycemic o ka lāʻau lapaʻau i ka like like.
Hōʻike nā haʻawina i ke bioequivalence ma nā ʻano o AUC a me C_max ʻO Galvus Met i ʻekolu mauʻokoʻa (50 mg / 500 mg, 50 mg / 850 mg a me 50 mg / 1000 mg) a me vildagliptin a me metformin i lawe ʻia i nā ʻaina kūpono i loko o nā papa i hoʻokaʻawale.
ʻAʻole pili ka meaʻai i ke kiʻekiʻe a me ka helu o ka hoʻopili ʻana o ka vildagliptin i ka hui ʻana o ka lāʻau Galvus Met. ʻĀina C_max a me AUC o nā metformin i ka hoʻohui o ka lāʻau Galvus Met i ka wā e lawe ana me ka meaʻai i hōʻemi ʻia e 26% a me 7%, kahi. Eia kekahi, ua hoʻolōʻihi ke kaila o ke metformin me ka ʻai ʻana i ka meaʻai, i hiki ai i ka nui o T_max (2 i 4 mau hola). ʻO ka loli like a C_max a ua hōʻike ʻia ʻo AUC me ka ʻaina meaʻai i ka hihia o ka hoʻohana ʻana i ka metformin hoʻokaʻawale, eia naʻe, ma ka hihia hope loa, ʻaʻole i nui nā hoʻololi.
ʻAʻole i like ka hopena o ka meaʻai ma ka pharmacokinetics o vildagliptin a me ka metformin i ka hoʻohui ʻana o ka lāʻau lapaʻau ʻo Galvus Met.
ʻŌpū a me ka lactation
No ka mea ʻaʻohe ʻike pono o ka hoʻohana ʻana i ka lāʻau Galvus Met i loko o nā wahine hāpai, ua contraindicated ka hoʻohana ʻana o ka lāʻau lapaʻau i ka wā hapai.
I loko o nā pilikia o ka metabolism glucose impaired i nā wahine hāpai, loaʻa ka nui o ka hoʻouluʻana i ka anomalies congenital, a me ka pinepine o ka neonatal morbidity a me ka make. E hoʻoikaika i ke ʻano o ka glucose koko i ka wā hapai, ua hōʻike ʻia ka insulin monotherapy.
ʻAʻole i mālama ʻia kahi hōʻike o ka hopena i ka ulu ʻana o ke kanaka.
Hoʻopau ka Metformin i ka waiū umauma. ʻAʻole i ʻike ʻia a hoʻopili ʻia ʻo vildagliptin i loko o ka waiū umauma. Ua hoʻohana ʻia ka hoʻohana ʻana i ka lāʻau Galvus Met i ka wā o ka hoʻoulu ʻana.
I nā hoʻokolohua hoʻokolohua, i ka wā e kuhikuhi ana i ka vildagliptin i nā wai he 200 mau manawa iʻoi aku ma mua o ka mea i hōʻike ʻia ʻia, ʻaʻole ia ka hopena o ka lāʻau lapaʻau i ka hōʻino o ka hoʻomohala ʻana i ka ulu mua ʻana o ka embryo a ʻaʻole i kau i kahi hopena teratogenic, a me ka pōkole pono ʻole. Ke hoʻohana nei i vildagliptin i hui pū me ka metformin ma kahi hapa o 1:10, ʻaʻohe pū ka hopena teratogenic. ʻAʻohe hopena maikaʻi i ka hūnā i nā kāne a me nā wahine me ka hoʻohana ʻana i ka metformin i nā dosis o 600 mg / kg / lā, kahi mea e kokoke ana i ka 3 mau manawa iʻoi aku ma mua o ka wai i ʻōlelo ʻia mai e pili ana i ka poʻe (ma nā ʻano o ka wahi papa o ke kino).
Hoʻohana no ka hana lawelawe lēwa
Nā koho: ka hana o ka ate hemahema.
No ka mea, i kekahi mau mea maʻi me ka hana aho lēwa, ua nānā ʻia ka lactic acidosis i kekahi mau hihia, ʻo ia paha kekahi o nā hopena ʻaoʻao o ka metformin, ʻaʻole pono ʻo Galvus Met i ka poʻe maʻi me nā maʻi o ka maʻi a i ʻole nā mea maʻi hepatic biochemical hepatic.